# Transcrição: IL11_Lifespan_Extension_Nature_2024

**Arquivo original:** IL11_Lifespan_Extension_Nature_2024.pdf
**Extraído em:** 2026-02-05 01:35:26 UTC
**Caracteres:** 221004

---

```
Article

Inhibition of IL-11 signalling extends
mammalian healthspan and lifespan

https://doi.org/10.1038/s41586-024-07701-9                        Anissa A. Widjaja1,12,13 ✉, Wei-Wen Lim1,2,12, Sivakumar Viswanathan1, Sonia Chothani1,
                                                                  Ben Corden2,3, Cibi Mary Dasan1, Joyce Wei Ting Goh1, Radiance Lim1, Brijesh K. Singh1,
Received: 18 April 2023
                                                                  Jessie Tan2, Chee Jian Pua2, Sze Yun Lim1, Eleonora Adami4, Sebastian Schafer1,
Accepted: 11 June 2024                                            Benjamin L. George1, Mark Sweeney5, Chen Xie2, Madhulika Tripathi1, Natalie A. Sims6,7,
                                                                  Norbert Hübner4,8,9, Enrico Petretto1,10, Dominic J. Withers5,11, Lena Ho1, Jesus Gil5,11,
Published online: 17 July 2024
                                                                  David Carling5,11 & Stuart A. Cook1,2,5,13 ✉
Open access

    Check for updates
                                                                  For healthspan and lifespan, ERK, AMPK and mTORC1 represent critical pathways and
                                                                  inflammation is a centrally important hallmark1–7. Here we examined whether IL-11, a
                                                                  pro-inflammatory cytokine of the IL-6 family, has a negative effect on age-associated
                                                                  disease and lifespan. As mice age, IL-11 is upregulated across cell types and tissues to
                                                                  regulate an ERK–AMPK–mTORC1 axis to modulate cellular, tissue- and organismal-level
                                                                  ageing pathologies. Deletion of Il11 or Il11ra1 protects against metabolic decline, multi-
                                                                  morbidity and frailty in old age. Administration of anti-IL-11 to 75-week-old mice for
                                                                  25 weeks improves metabolism and muscle function, and reduces ageing biomarkers
                                                                  and frailty across sexes. In lifespan studies, genetic deletion of Il11 extended the lives
                                                                  of mice of both sexes, by 24.9% on average. Treatment with anti-IL-11 from 75 weeks
                                                                  of age until death extends the median lifespan of male mice by 22.5% and of female
                                                                  mice by 25%. Together, these results demonstrate a role for the pro-inflammatory
                                                                  factor IL-11 in mammalian healthspan and lifespan. We suggest that anti-IL-11 therapy,
                                                                  which is currently in early-stage clinical trials for fibrotic lung disease, may provide
                                                                  a translational opportunity to determine the effects of IL-11 inhibition on ageing
                                                                  pathologies in older people.



The major signalling mechanisms that regulate lifespan across spe-                                  dysfunctional adaptive immune system that is characterized by immu-
cies include ERK, STK11 (also known as LKB1), AMPK, mTORC1 and                                      nosenescence and thymic involution along with inappropriate activa-
IGF1–insulin modules1–3. These pathways are collectively perturbed in                               tion of innate immune genes such as IL-67,16,18,19. The pro-inflammatory
old age to activate hallmarks of ageing, which include mitochondrial                                signalling factors NF-κB and JAK–STAT3 are specifically implicated in
dysfunction, inflammation and cellular senescence1. In aged organisms,                              ageing and JAK inhibitors can alleviate age-related dysfunction2,20,21.
the AMPK–mTORC1 axis is uniquely important for metabolic health,                                       We proposed that IL-11, a pro-inflammatory and pro-fibrotic mem-
with notable effects in adipose tissue8,9, and therapeutic inhibition of                            ber of the IL-6 family22, may promote age-associated pathologies and
mTOR extends lifespan in mice10,11.                                                                 reduce lifespan. This premise was founded on studies showing that IL-11
   Ageing studies to date have focused largely on lifespan extension,                               can activate ERK–mTORC1 and/or JAK–STAT322–25 (Fig. 1a), the observa-
particularly in yeast, worms and fruit flies, but lifespan extension                                tion that IL-11 is upregulated in older people26 and the fact that IL-11 is
does not necessarily reflect longer healthspan12–14. There is a need for                            increasingly recognized to have a role in senescence, a hallmark of age-
integrated studies to determine the effects of interventions on both                                ing27. Here, using a range of genetic and pharmacological approaches,
healthspan and lifespan. Laboratory mice are particularly suited for                                we tested the hypothesis that IL-11 signalling has a negative effect on
such experiments, as ageing pathologies that are important for human                                healthspan and lifespan in mice.
wellbeing and function are apparent and lifespan studies are well estab-
lished in mice1,15.
   The importance of chronic sterile inflammation for ageing pathol-                                IL-11 is upregulated with age
ogies is increasingly recognized and inflammation itself is a central                               We determined IL-11 expression in the liver, visceral gonadal white
hallmark of ageing7,16,17. In simplified terms, ageing is associated with a                         adipose tissue (vWAT) and skeletal muscle (gastrocnemius) in

1
 Cardiovascular and Metabolic Disorders Program, Duke–National University of Singapore Medical School, Singapore, Singapore. 2National Heart Research Institute Singapore, National Heart
Centre Singapore, Singapore, Singapore. 3Barts Heart Centre, Barts Health NHS Trust, London, UK. 4Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in
the Helmholtz Association (MDC), Berlin, Germany. 5MRC Laboratory of Medical Sciences, London, UK. 6Bone Biology and Disease Unit, St Vincent’s Institute of Medical Research, Melbourne,
Victoria, Australia. 7Department of Medicine, St Vincent’s Hospital, The University of Melbourne, Melbourne, Victoria, Australia. 8DZHK (German Centre for Cardiovascular Research), Partner
Site Berlin, Berlin, Germany. 9Charité–Universitätsmedizin, Berlin, Germany. 10Institute for Big Data and Artificial Intelligence in Medicine, School of Science, China Pharmaceutical University,
Nanjing, China. 11Institute of Clinical Sciences, Faculty of Medicine, Imperial College, London, UK. 12These authors contributed equally: Anissa A. Widjaja, Wei-Wen Lim. 13These authors jointly
supervised this work: Anissa A. Widjaja, Stuart A. Cook. ✉e-mail: anissa.widjaja@duke-nus.edu.sg; stuart.cook@duke-nus.edu.sg



                                                                                                                                             Nature | Vol 632 | 1 August 2024 | 157
Article
  a                            IL-11                                            b                                                                                                                            c
                                                                                         Liver                                             Age (weeks)
                              IL11RA
                                                                                                                   12             25        50         75               110
                                                                                                                                                                                               kDa
                              gp130
                                                                                         IL-11                                                                                                 25
                                                                                       GAPDH                                                                                                                  Age (weeks)      12                25      50      75   110




                                                                                                                                                                                                                                                                                       IL-11/GAPH (FC)
                                                                                                                                                                                               35
        STAT3                       ERK                                               p-ERK1/2
                                                                                                                                                                                               40                  Gastroc     1.00 1.06 1.96 4.21 9.53                           10
                                                                                     p-p90RSK                                                                                                  70
                                                  LKB1          AMPK
                                                                                                                                                                                                                                                                                  5
                                                                                       p-LKB1                                                                                                  50                    vWAT      1.00 2.08 4.19 7.95 12.68
           IL-6, p90RSK
           IL-8,                                                                       p-AMPK                                                                                                  50
                                                                MTOR
           IL-33,                                                                     p-mTOR                                                                                                   260
           CCL2                                                                                                                                                                                100
                                                                                     p-p70S6K
                                                S6RP            p70S6K                 p-S6RP                                                                                                  25

  d      Il11EGFP/+
                                            Il11EGFP/+ (10 weeks)                                                                        Il11EGFP/+ (110 weeks)                                                                 WT (110 weeks)
      SLC10A1 EGFP DAPI




  e                                                                                                f                                                                       g
                                       10 weeks              110 weeks
                                                                                                                                     0.0472                                                              0.0129                                                    0.0035
                                    WT      Il11ra1–/–   WT        Il11ra1–/–                                       50                                                                    50         <0.0001                                    100           <0.0001
                                                                                kDa                                           <0.0001 <0.0001
                                                                                                                                                           WT                                               <0.0001                                                    <0.0001
                                                                                                 Body weight (g)




      p-ERK                                                                     40                                  40                                     Il11ra1–/–                     40                                                     90




                                                                                                                                                                                                                                Lean mass (%)
    p-LKB1                                                                      50                                  30                                                   Fat mass (%)     30                                                     80
   p-AMPK                                                                       70
                                                                                                                    20                                                                    20                                                     70
   p-mTOR                                                                       260
                                                                                100                                 10                                                                    10                                                     60
  p-p70S6K
    p-S6RP                                                                      35                        Male          0
                                                                                                                    Female                                                                 0     Male      Female                                50       Male      Female
               p16                                                              15                     Variation (%) P value                                                                   Variation (%) P value                                    Variation (%) P value
               p21                                                              15          Interaction     0.87        0.331                                           Interaction                   5.20         0.0106       Interaction                 4.08        0.0178
                                                                                                   Sex      4.60       0.0287                                                  Sex                   32.08       2.21 × 10–8           Sex                  33.59     4.52 × 10–9
    GAPDH                                                                       35           Genotype      49.70     1.17 × 10–9                                         Genotype                    19.16       4.93 × 10–6     Genotype                   21.22     8.67 × 10–7


  h                                    Young      Old                                                         i                                0.0146                   0.0169                               j
                                                                                                                                                                                                                                                      Il11+/+         Il11–/–
                              1.5      <0.0001 0.0014             0.0046 0.0018                                                          0.0002 <0.0001           <0.0001<0.0001
                                                                                                                            1.5                                                                                                                 Young     Old    Young      Old
       Telomere length (FC)




                                                                                                                                                                                                                                                                                       kDa
                                                                                                                                                                                                                           IL-11
                                                                                                           mtDNA copy
                                                                                                           number (FC)




                              1.0                                                                                           1.0                                                                                  Liver                                                                 25
                                                                                                                                                                                                                         GAPDH                                                         35
                              0.5                                                                                           0.5                                                                              Gastroc       IL-11                                                       25
                                                                                                                                                                                                                         GAPDH                                                         35
                               0          Male                        Female                                                 0          Male                         Female                                                IL-11                                                       25
                                                                                                                                                                                                              Soleus
                               Variation (%) P value         Variation (%) P value                                           Variation (%) P value           Variation (%) P value                                       GAPDH                                                         35
  Interaction                       4.70         0.0741         1.55        0.309            Interaction                               1.43       0.275         2.21                       0.142                           IL-11                                                       25
         Sex                                                                                        Sex                                                                                                          vWAT
                                    9.25          0.014         15.10      0.00258                                                     24.99   4.03 × 10–5      20.53                   4.83 × 10–5                      GAPDH                                                         35
   Genotype                         32.13      2.37 × 10–5      19.15      0.00082            Genotype                                 29.64    0.000011        28.51                   3.70 × 10–6

Fig. 1 | The IL-11–ERK–mTORC1 signalling module is upregulated in ageing                                                                                male wild-type and Il11ra1−/− mice (n = 5 per group); total proteins are shown in
and associated with senescence and metabolic decline. a, Signalling pathway                                                                             Extended Data Fig. 2a. f,g, Body weight (f) and percentages of fat and lean mass
by which IL-11 induces canonical STAT3 activation and non-canonical ERK                                                                                 (male wild-type, n = 12; male Il11ra1−/−, n = 16; female wild-type, n = 15; female
activation, LKB1–AMPK inactivation and mTOR activation. b, Western blots of                                                                             Il11ra1−/−, n = 13). h,i, Telomere length (h) and mtDNA copy number (i) in liver
the indicated liver phosphoproteins from male mice aged 12–110 weeks (n = 5                                                                             from young (10-week-old) and old (110-week-old) male and female wild-type
per group); total (phosphorylated plus unphosphorylated) proteins are shown                                                                             and Il11ra1−/− mice (young male wild-type, n = 8; young male Il11ra1−/−, n = 7; old
in Extended Data Fig. 1a. c, Heat map showing densitometry of IL-11 protein                                                                             male wild-type, n = 11; old male Il11ra1−/−, n = 17; young female wild-type, n = 7;
expression normalized to GAPDH (immunoblots are shown in Extended Data                                                                                  young female Il11ra1−/−, n = 8; old female wild-type, n = 15; old female Il11ra1−/−,
Fig. 1c) in gastrocnemius (gastroc) and vWAT from 12- to 110-week-old male                                                                              n = 13). FC, fold change. j, IL-11 and GAPDH immunoblots from the indicated
mice (n = 5 per group). d, Representative immunofluorescence images (scale                                                                              organs of 12- and 105-week-old male wild-type and Il11−/− mice (liver and soleus,
bars, 100 µm) of liver EGFP and SLC10A1 expression from 10 and 110-week-old                                                                             n = 4 per group; vWAT and gastrocnemius, n = 6 per group). f–i, Data are
Il11-EGFP mice and age-matched wild-type (WT) controls (n = 3 per group).                                                                               mean ± s.d.; the table below each panel shows summary statistics from two-way
Scale bars, 100 μm. e, Western blot of liver extracts from 10- and 110-week-old                                                                         ANOVA with Sidak’s correction. For gel source data, see Supplementary Fig. 1.



mice over a time course of ageing, which revealed progressive up-                                                                                       an IL-11 signalling module, in liver and muscle (Fig. 1b and Extended
regulation of IL-11 in all tissues (Fig. 1b,c and Extended Data Fig. 1a,b).                                                                             Data Fig. 1c). IL-11 up-regulation was confirmed in livers, vWAT and
With age, there was progressive activation of ERK–p90RSK, inactiva-                                                                                     skeletal muscle of two-year-old male and female mice (Extended Data
tion of LKB1–AMPK and mTOR–p70S6K activation, which comprise                                                                                            Fig. 1d).


158 | Nature | Vol 632 | 1 August 2024
   To identify the cell types that express Il11 in old mice, we queried the    of hepatocytes revealed significant IL-11-stimulated ERK- and
Tabula Muris Senis28, which was uninformative, likely as Il11 is expressed     mTORC1-dependent regulation of the majority of these proteins
at low levels and IL-11 is largely translationally regulated25. To better      (Extended Data Fig. 3e–g).
identify IL-11-expressing cells in tissues from old mice, we performed           Accumulation of senescent cells contributes to ageing pathologies.
immunohistochemistry in tissues from aged Il11-EGFP reporter mice29.           We modelled replicative senescence by serially passaging human fibro-
In two-year-old Il11-EGFP mice, IL-11 was apparent in parenchymal cells        blasts in the presence of a neutralizing IL11RA antibody (X209) or an
(hepatocytes in liver, adipocytes in vWAT and myocytes in skeletal             IgG control29,34. We observed passage-dependent phosphorylation
muscle) and also seen in stromal, epithelial and endothelial cells across      of ERK–mTORC1, NF-κB and STAT3 along with increased amounts of
tissues and in nerves in skeletal muscle (Fig. 1d and Extended Data            senescence markers—these effects were IL-11-dependent with evidence
Fig. 1e–g). Thus, IL-11 is expressed in diverse cell types in different tis-   of both autocrine and paracrine effects (Extended Data Fig. 4a–d).
sues with ageing.                                                              Telomere lengths and mtDNA copy numbers were similar between
                                                                               early passage (passage 4 (P4)) cells and X209-treated late passage (P14)
                                                                               cells, whereas these phenotypes were reduced in IgG-treated P14 cells
IL-11 is associated with senescence                                            (Extended Data Fig. 4e,f). Basal metabolic respiration was impaired in
To explore further the relationship between IL-11 up-regulation and            IgG-treated P14 fibroblasts, whereas X209-treated P14 cells were similar
ERK–mTOR activation in tissues of old mice, we studied ten-week-old            to P4 fibroblasts (Extended Data Fig. 4g,i).
and two-year-old Il11ra1−/− mice and wild-type littermate controls30,31. On
immunoblots of liver, vWAT and gastrocnemius extracts, old wild-type
mice exhibited increased phosphorylated (p)-ERK and p-p90RSK,                  Deletion of Il11 in female mice
increased p-LKB1 leading to reduced p-AMPK, and increased levels of            To support the data generated in Il11ra1-deleted mice on a mixed
p-mTOR, p-p70S6K and p-S6RP (Fig. 1e and Extended Data Fig. 2a–c).             C57BL6/129 genetic background30 and to more deeply dissect
Levels of the canonical senescence markers p16Inka4 and p21Waf1/Cip1 were      age-related effects, we studied young (3-month-old) and aged
increased in tissues of old wild-type mice. By contrast, the phospho-          (2-year-old) female mice with deletion of Il11 (Il11−/−) on a C57BL6/J
rylation status of these various kinases and S6RP, and levels of p16 and       background31.
p21 were similar between old Il11ra1−/− mice and young wild-type mice             Immunoblots confirmed IL-11 up-regulation across tissues in old age
(Fig. 1e and Extended Data Fig. 2a–c).                                         in this additional strain (Fig. 1m). Old female Il11−/− mice had lower body
                                                                               weights and fat mass and preserved lean mass (Fig. 2a–c). The frailty
                                                                               score15 of old female Il11−/− mice was lower than that of old wild-type
Deletion of Il11ra1 improves metabolism                                        mice and their body temperatures were mildly increased (Fig. 2d and
Compared with wild-type littermate controls, two-year-old Il11ra1−/−           Extended Data Fig. 5a). Lower frailty scores were largely driven by
mice had lower body weights (Fig. 1f), and female Il11ra1−/− mice had          improvements in tremor, loss of fur colour, gait disorders and vestibular
decreased fat mass and increased lean mass (Fig. 1g). Il11ra1−/− mice of       disturbance (Supplementary Table 1). Muscle strength was higher in
both sexes had slightly higher core body temperatures than wild-type           both young and old Il11−/− mice (a phenomenon that was observed for
controls (Extended Data Fig. 2d). Old Il11ra1−/− mice of both sexes had        some other phenotypes) compared with age-matched controls (Fig. 2e
lower indexed vWAT mass (vWAT weight normalized to body weight)                and Extended Data Fig. 5b).
and increased indexed gastrocnemius mass (Extended Data Fig. 2e).                 Chronic inhibition of mTORC1 with rapamycin can cause glucose
Liver indices were similar between genotypes, whereas liver triglyceride       intolerance owing to indirect inhibition of mTORC235. It was therefore
levels were lower in Il11ra1−/− mice (Extended Data Fig. 2e,f).                important to more fully assess the effects of IL-11 inhibition on liver
   Serum cholesterol and triglyceride levels were higher in old wild-type      function, metabolism and glucose utilization in old mice. As wild-type
mice than in Il11ra1−/− littermates (Extended Data Fig. 2g,h). Livers          mice aged, there were increases in serum AST, ALT, cholesterol and tri-
of old Il11ra1−/− mice of both sexes exhibited reduced expression of           glycerides, which were collectively mitigated in old Il11−/− mice (Fig. 2f
pro-inflammatory (Ccl2, Ccl5, Tnf and Il1b) and fatty acid synthesis           and Extended Data Fig. 5c,d). Glucose tolerance test (GTT) and insulin
(Acc, Fasn and Srebp1c) genes (Extended Data Fig. 2i,j). Serum alanine         tolerance test (ITT) profiles of old Il11−/− mice were similar to those of
transaminase (ALT) and aspartate aminotransferase (AST) levels, mark-          young wild-type mice, whereas GTTs and ITTs of old wild-type mice
ers of hepatocyte damage, were increased in old wild-type mice but not         showed impairment (Fig. 2g and Extended Data Fig. 5e,f). Indexed
in old Il11ra1−/− mice (Extended Data Fig. 2k,l).                              skeletal muscle mass was greater in both young and old Il11−/− mice
   We assessed telomere lengths and mitochondria DNA (mtDNA) copy              compared with the equivalent wild-type mice (Extended Data Fig. 5g).
numbers—biomarkers associated with biological age1,32—in liver and                Compared with old wild-type controls, old Il11−/− mice had reduced
gastrocnemius and found significant preservation of these phenotypes           liver mass indices and liver triglyceride content (Extended Data
in tissues of old Il11ra1−/− mice (Fig. 1h,i and Extended Data Fig. 2m,n).     Fig. 5h,i). Indexed vWAT and inguinal subcutaneous white adipose
                                                                               tissue (scWAT) masses were reduced in old Il11−/− mice, whereas brown
                                                                               adipose tissue (BAT) mass was unchanged (Fig. 2h and Extended Data
IL-11 induces senescence in human cells                                        Fig. 5j). To examine the potential role of de novo lipogenesis in aged tis-
IL-11 is linked with senescence—we therefore explored the direct               sue, we profiled the expression of fatty acid synthesis genes in vWAT and
effects of IL-11 on senescence in human cell types corresponding to            found their expression to be increased with age in old wild-type mice
those found to express IL-11 in aged mice (Fig. 1d and Extended Data           but not in old Il11−/− mice (Fig. 2i). Similar to Il11ra1−/− mice (Extended
Fig. 1e–g). Stimulation of human fibroblasts or hepatocytes with IL-11         Data Fig. 2b,c), activation of the ERK–mTORC1 axis and up-regulation
activated ERK–mTOR, increased levels of p16 and p21, and reduced               of senescence markers were mitigated in vWAT and gastrocnemius of
expression of PCNA and cyclin D1, which was prevented by U0126 or              old Il11−/− mice (Fig. 2j and Extended Data Fig. 5k,l). Pro-inflammatory
rapamycin (Extended Data Fig. 3a,b). Supernatants of IL-11-stimulated          gene expression was increased in vWAT of old wild-type mice but not
fibroblasts had increased amounts of senescence-associated secretory           in that of old Il11−/− mice (Extended Data Fig. 5m).
phenotype factors, and this increase was inhibited by U0126 or rapamy-            Telomere lengths and mtDNA content in liver, skeletal muscle and
cin (Extended Data Fig. 3c,d). Deeper profiling of mTORC1-dependent            vWAT were reduced in old wild-type mice and these effects were attenu-
senescence-associated secretory phenotype factors (IL-6, IL-8, LIF,            ated by Il11 deletion (Fig. 2k,l). Serum IL-6 levels were increased in old
VEGFA, HGF, CCL2, CXCL1, CXCL5, CXCL6 and CCL2033) in supernatants             wild-type mice but not in old Il11−/− mice (Extended Data Fig. 2n).


                                                                                                               Nature | Vol 632 | 1 August 2024 | 159
Article
      a                                                                                           b                                                                                                                               c                                                                                                                                                                 d
                                                                                                                                                    0.0004                                                                                                             0.0264                                                                                                                                                             <0.0001
                                                                                                                                                       <0.0001                                                                                                          <0.0001                                                                         <0.0001
                                                                                                                                   50                                                                                                           40                                                                              100                                                                                 10

                                                                                                                                   40                                                                                                                                                                                            90
                                                                                                                                                                                                                                                30




                                                                                                                                                                                                                                                                                                                Lean mass (%)
                                                                                                Body weight (g)




                                                                                                                                                                                                                                Fat mass (%)




                                                                                                                                                                                                                                                                                                                                                                                                    Frailty score
                                                                                                                                                                                                                                                                                                                                                                                                                     5
                                                                                                                                   30                                                                                                                                                                                            80
                                                                                                                                                                                                                                                20
                                                                                                                                   20                                                                                                                                                                                            70
                                                                                                                                                                                                                                                                                                                                                                                                                     0
                                                                                                                                                                                                                                                10
                                                                                                                                   10       Young Il11+/+        Old Il11+/+                                                                                                                                                     60

                                                                                                                                   0        Young Il11–/–        Old Il11–/–                                                                     0                                                                               50                                                                                 –5
                                                                                                          Variation (%)    P value                                                                                                         Variation (%)   P value                                                        Variation (%)   P value                                                                             Variation (%)     P-value
                                                                                              Interaction    8.337       7.57 × 10–6                                                                                           Interaction    10.87      2.17 × 10–6                                          Interaction    7.909      5.14 × 10–5                                        Interaction                            12.4        4.09 × 10–9
                                 Old Il11+/+                          Old Il11–/–
                                                                                               Genotype       15.62     3.35E × 10–7                                                                                            Genotype       24.68     1.62 × 10–10                                          Genotype        29.5     3.21 × 10–11                                        Genotype                              13.34       1.61 × 10–9
                                                                                                     Age      45.78     1.89 × 10–13                                                                                                  Age      32.23     3.25 × 10–12                                                Age      29.41     3.37 × 10–11                                              Age                             52.93       2.14 × 10–19


      e                                                                                                     f                                                                                                                                          0.0451                                   g                                               GTT                                                                      ITT




                                                                                                                                                                                                                                                                                                                                                                                          <0.0001
                                                                        0.0027                                                                                                                                                                         <0.0001                                                25                                                                    15                                                         Young Il11+/+
                                  15                                                                                                400                                                                                  300
                                                                                                     Serum cholesterol (mg dl–1)




                                                                                                                                                                                                                                                                                                                                                                                                                                               Young Il11–/–




                                                                                                                                                                                          Serum triglyceride (mg dl–1)
                                                                     <0.0001                                                                       0.0002    <0.0001




                                                                                                                                                                                                                                                                                                                                <0.0001
                                                                                                                                                                                                                                                                                                              20
    (g per g body weight)




                                                                                                                                                                                                                                                                                               Glucose (mM)




                                                                                                                                                                                                                                                                                                                                                                     Glucose (mM)
                                                                                                                                                                                                                                                                                                                                                                                                                                               Old Il11+/+
      Full body strength




                                                                                                                                                                                                                                                                                                                                                                                    10
                                                                                                                                    300                                                                                                                                                                       15
                                  10                                                                                                                                                                                     200                                                                                                                                                                                                                   Old Il11–/–

                                                                                                                                    200                                                                                                                                                                       10
                                                                                                                                                                                                                                                                                                                                                                                     5
                                    5                                                                                                                                                                                    100                                                                                    5
                                                                                                                                    100
                                                                                                                                                                                                                                                                                                                0                                                                    0
                                    0                                                                                                   0                                                                                  0                                                                                                     0      30           60     90                             0                        30         60        90 Time (min)
                                                                                                                                                                                                                                                                                                                                Variation (%)          P value                   Variation (%)    P value
                                                          Variation (%)   P value                                                           Variation (%)      P value                                                                         Variation (%)         P value                Interaction                            2.575            6.63 × 10–33     Interaction    3.475      4.22 × 10–18
                             Interaction                      2.33        0.00668                     Interaction                              2.507           0.0901                                               Interaction                   6.102             0.00705                  Genotype                               59.63           9.56 × 10–100     Genotype       49.39     1.61 × 10–52
                              Genotype                        52.01     1.11 × 10–7                    Genotype                                 28.68        4.49 × 10–7                                             Genotype                      17.01           2.26 × 10–5                     Age                              23.37           2.69 × 10–21            Age      25.15      3.4 × 10–20
                                    Age                       17.71     4.65 × 10–10                         Age                                19.96        1.25 × 10–5                                                   Age                     31.75           6.04 × 10–8                 Subject                              3.314           1.38 × 10–29        Subject      4.042      2.1 × 10–12


  h                                                             vWAT                                          scWAT                                                 i                                                      Acc1                                            Fasn                                                   Srebp1c                      j                         10 weeks                                    105 weeks
                                                                                                                                                                                                                                                                             0.0239
                                 0.08                                                                                                                                                5                                                                                                                                                                                               WT                             Il11–/–         WT        Il11–/–
  Organ weight/body weight




                                                                                                                                    <0.0001                                                                                                                                                                                                                                                                                                              kDa
                                                                        <0.0001                                                                                                                                                                                    <0.0001
                                                                                                                                                              Gene expression (FC)




                                                                                                                                                                                     4                                         <0.0001                                                                                                                            p-ERK
                                 0.06                                                                                                                                                                                                                                                                                                                                                                                                                    40
                                                                                                                                                                                                                                                           0.0239                 <0.0001                                                 <0.0001
                                                                                                                                                                                                                                                                                                                                                             p-p90RSK                                                                                    70
                                                                                                                                                                                     3
                                 0.04                                                                                                                                                                                                                                                                                                                          p-LKB1                                                                                    50
                                                                                                                                                                                     2                                                                                                                                                                        p-AMPK                                                                                     50
                                 0.02                                                                                                                                                1                                                                                                                                                                        p-MTOR                                                                                     260
                                                                                                                                                                                                                                                                                                                                                                                                                                                         100
                                                                                                                                                                                                                                                                                                                                                             p-p70S6K
                                    0                                                                                                                                                0
                                                                                                                                                                                                                                                                                                                                                               p-S6RP                                                                                    35
                                        Variation (%)   P value    Variation (%)   P value                                                                                           Variation (%)                               P value                Variation (%)               P value    Variation (%)                                    P value
                                                                                                                                                                                                                                                                                                                                                                    p16                                                                                  15
 Interaction                                15.3      2.42 × 10–9     8.628       0.000737                                                             Interaction                      8.596                                   0.000151                   6.091                    0.00068       12.41                                       9.22 × 10–6
                                                                                                                                                                                                                                                                                                                                                                    p21                                                                                  25
  Genotype                                  25.02     2.29 × 10–12     21.04     1.21 × 10–6                                                            Genotype                         25.93                                 4.65 × 10–9                  31.97                 8.08 × 10–11     30.63                                      4.86 × 10–10
        Age                                 28.99     2.21 × 10–13     18.67     3.53 × 10–6                                                                  Age                        27.9                                  1.84 × 10–9                  26.47                 1.07 × 10–9      14.87                                      1.85 × 10–6      GAPDH                                                                                     35


                                         k                                     Liver                                                        vWAT                                     Gastrocnemius                                                             l                                              Liver                                        vWAT                          Gastrocnemius

                                                                                                                                              0.0007
                                                               1.5                  <0.0001                                                                                                                                                                                       2.0                          0.0033
                                                                                                                                                                                                   <0.0001                                                                                                                                                   <0.0001
                                                                                                                                               <0.0001                                                                                                                                                                                                                                                               <0.0001
                                        Telomere length (FC)




                                                                                       0.0002                                                                                                                                                                                                  <0.0001 0.0003
                                                                                                                                                                                                                                                                                  1.5
                                                                                                                                                                                                                                                                    number (FC)
                                                                                                                                                                                                                                                                    mtDNA copy




                                                               1.0
                                                                                                                                                                                                                                                                                  1.0

                                                               0.5
                                                                                                                                                                                                                                                                                  0.5


                                                                0                                                                                                                                                                                                                 0.0

                                              Variation (%)                            P value     Variation (%) P value                                               Variation (%)   P value                                                                                          Variation (%)   P value                                 Variation (%)   P value                  Variation (%)   P value
                                  Interaction    3.754                                  0.0163        2.484       0.0838                                                  6.312       0.000862                                                                 Interaction                 2.963        0.0771                                     3.384         0.0143                     3.572        0.00887
                                   Genotype       4.611                                0.00818         11.86     0.000344                                                  6.532      0.000722                                                                  Genotype                    9.198      0.00258                                      17.41     5.96 × 10–7                    14.92     1.16 × 10–6
                                         Age      60.61                              3.08 × 10 –13     43.46     2.1 × 10–9                                                59.39     1.74 × 10–14                                                                     Age                   40.91     2.21 × 10–8                                   47.61     1.41 × 10–12                   52.64     6.84 × 10–14


Fig. 2 | Female Il11-deleted mice are protected from age-associated obesity,                                                                                                                                                                                   levels of p16, p21 and GAPDH (j). n = 6 per group. Western blots for the respective
frailty, and metabolic decline. a, Representative photograph of 105-week-old                                                                                                                                                                                   total proteins are shown in Extended Data Fig. 5k. k,l, Telomere length and
female wild-type and Il11−/− mice. b–g, Body weight (b), percentage of fat                                                                                                                                                                                     mtDNA copy number (l) in vWAT from young and old female wild-type and Il11−/−
and lean mass (normalized to body weight), frailty score (d), full body grip                                                                                                                                                                                   mice. b–i,k–l, Data are mean ± s.d. (young wild-type, n = 8; young Il11−/−, n = 9;
strength (e), serum cholesterol and triglycerides (f), and GTT and ITT (g) of                                                                                                                                                                                  old wild-type, n = 16; old Il11−/−, n = 18; except for h (scWAT): young wild-type,
young (12-week-old) and old (105-week-old) female wild-type and Il11−/− mice.                                                                                                                                                                                  n = 5; young Il11−/−, n = 7; old wild-type and Il11−/−, n = 16). Two-way ANOVA with
h–j, Indexed vWAT and scWAT weight (h), relative vWAT mRNA expression level                                                                                                                                                                                    Sidak’s correction (b–f,h,i,k,l); two-way repeated measures ANOVA with Sidak’s
of Acc1, Fasn and Srebp1c (i), and western blot showing activation status of                                                                                                                                                                                   correction (h). For gel source data, see Supplementary Fig. 1.
ERK1/2, p90RSK, LKB1, AMPK, mTOR, p70S6K and S6RP and protein expression




                                                                                                                                                                                                                                                               young mice, whereas those of old wild-type controls were impaired
Deletion of Il11 in male mice                                                                                                                                                                                                                                  (Extended Data Fig. 6g).
Detrimental changes in body habitus, body weight, fat mass, lean mass                                                                                                                                                                                             Metabolic cage analysis revealed that the respiratory exchange ratio
and frailty scores (driven by tremor, coat condition and fur loss) were                                                                                                                                                                                        (RER) was overall higher in old Il11−/− mice compared with old wild-type
mitigated and body temperatures were mildly increased in old male                                                                                                                                                                                              mice (Extended Data Fig. 6h). After a period of starvation, refeeding
Il11−/− mice (Extended Data Fig. 6a–e and Supplementary Table 2). Mus-                                                                                                                                                                                         resulted in a greater increase of RER in old Il11−/− mice, consistent with
cle strength was higher in both young and old Il11−/− mice compared with                                                                                                                                                                                       better metabolic flexibility36 (Extended Data Fig. 6h). Whereas old
age-matched wild-type controls, as seen for female mice (Extended Data                                                                                                                                                                                         Il11−/− mice were leaner and weighed less than wild-type controls, they
Fig. 6f). GTT and ITT profiles of old Il11−/− mice were similar to those of                                                                                                                                                                                    consumed more food and had similar levels of locomotor activity


160 | Nature | Vol 632 | 1 August 2024
(Extended Data Fig. 6h). Calorie-losing enteropathy of Il11−/− mice was       mice22,39. We quantified fibrosis in aged vWAT, skeletal muscle and liv-
excluded by bomb calorimetry (Extended Data Fig. 6i).                         ers of old mice across experimental groups, which showed reversal of
   Sarcopenia was apparent in the muscle of old wild-type mice, and           tissue fibrosis across organs of mice receiving X203 (Fig. 3l).
this effect was less pronounced in old Il11−/− mice, which exhibited             Compared with 75-week-old mice, vWAT from mice receiving IgG for
greater indexed muscle mass even when young, as seen for female mice          25 weeks had increased activation of the IL-11–mTORC1 axis and higher
(Extended Data Fig. 6j,k). Indexed liver weights were similar between         expression of senescence markers (Fig. 3m and Extended Data Fig. 7i).
mice of both genotypes (Extended Data Fig. 6l). As for female mice,           By contrast, mice receiving X203 had reduced ERK–mTOR activity and
perhaps the most notable beneficial difference associated with loss           decreased expression of p21 and p16 (Fig. 3m and Extended Data Fig. 7i).
of Il11 function in old male mice was seen for vWAT mass, whereas BAT         One-hundred-week-old untreated and IgG-treated mice had telomere
mass was similar across genotypes and ages (Extended Data Fig. 6m).           attrition and a reduction in mtDNA copy number, which were not seen
An incidental finding of enlarged seminal vesicles, an idiosyncratic          in X203-treated mice (Extended Data Fig. 7j,k).
age-specific phenomenon in old male mice37, was more common in
old wild-type mice compared with old Il11−/− mice (wild-type: 11 out of
15, Il11−/−: 1 out of 14; P = 0.0003) (Supplementary Table 2).                Anti-IL-11 therapy in old female mice
                                                                              We also examined the effects of anti-IL-11 therapy on ageing pathologies
                                                                              in old female mice (Extended Data Fig. 8a). Old female mice receiving
Anti-IL-11 therapy in old male mice                                           X203 lost body weight, whereas those administered with IgG gained
Studies of germline genetic loss of function on healthspan and/or             weight (Extended Data Fig. 8b). At the end of the study period, mice
lifespan should be complemented by interventions in late life only to         on X203 had lower fat mass, higher lean mass and better GTTs and ITTs
identify phenotypes that are carried through from younger animals             than at the outset, whereas the opposite effect was observed in mice
and for translational relevance. This is pertinent to the current study, in   on IgG (Extended Data Fig. 8c,d). Frailty scores were similar between
which some beneficial effects of Il11 loss of function (such as increased     study groups at the start of the experiment and these scores progressed
muscle mass and strength) are apparent even in young Il11-deleted mice        in mice receiving IgG but not in mice receiving X203 (Extended Data
(Fig. 2 and Extended Data Fig. 6). To achieve this goal, we administered      Fig. 8e and Supplementary Table 4). Muscle strengths were greater
a neutralizing IL-11 antibody (X203) or IgG control to aged mice and          than starting levels in female mice receiving X203 and core body tem-
studied healthspan indices29,38 (Fig. 3a).                                    peratures were mildly increased (Extended Data Fig. 8f–h).
   Compared with controls, mice receiving X203 from 75 to 100 weeks
of age progressively lost body weight that was defined by a reduction in
indexed fat mass (Fig. 3b,c). Impaired glucose metabolism was appar-          Anti-IL-11 restores white adipose beiging
ent across experimental groups at study start that was improved in            To further dissect molecular mechanisms, we performed bulk
mice receiving X203, whereas IgG had no effect (Fig. 3d). Frailty scores      RNA sequencing (RNA-seq) of vWAT, gastrocnemius and liver from
were mildly increased across experimental groups at study initiation          IgG-treated or anti-IL-11-treated 100-week-old mice (Supplementary
(Fig. 3e). Over the study period, mice receiving no treatment or IgG          Table 5). Across tissues, mice receiving anti-IL-11 had the most signifi-
exhibited frailty progression (for example, tremor and gait disorder),        cant gene set enrichment scores for hallmarks of oxidative phospho-
whereas those on X203 did not (Fig. 3e and Supplementary Table 3).            rylation and metabolism, whereas scores for markers of inflammation,
Muscle strengths of 100-week-old mice receiving anti-IL-11 were higher        EMT and JAK–STAT3 signalling were reduced (Fig. 4a).
than aged-matched controls receiving IgG or untreated, and also higher           In aged vWAT, genes associated with senescence (Cdkn2a, Tnf, Il10,
than those of 75-week-old mice at the start of the experiment (Fig. 3f        Il1b, Bst1, Irg1, Parp14, Itgax and Itgam) as identified by The Tabula Muris
and Extended Data Fig. 7a).                                                   Senis28 were upregulated, an effect that was mitigated by anti-IL-11
   After six weeks of antibody administration, mice were studied in           therapy (Fig. 4b and Extended Data Fig. 9a). A similar, although less
metabolic cages. The RER of mice receiving X203 was higher than that of       pronounced inhibition of senescence markers was seen in muscles
IgG-treated mice but lower than that of a cohort of young mice (Fig. 3g       and livers of mice receiving anti-IL-11.
and Extended Data Fig. 7b), suggesting that X203 slows age-associated            More detailed study of the vWAT transcriptome revealed that the gene
metabolic inflexibility. Administration of X203 was associated with           that was most upregulated by anti-IL-11 genome-wide was Ucp1, which
higher core temperatures and increased food intake, whereas locomo-           is important for the development of thermogenic ‘beige’ adipocytes
tor activity levels and faecal caloric densities were similar between         in white adipose tissue (WAT) deposits40,41 (Fig. 4c and Supplementary
study groups (Fig. 3h and Extended Data Fig. 7b,c).                           Table 5). On closer inspection, we found up-regulation of a larger beig-
   Mice left untreated or given IgG had increased serum cholesterol,          ing programme (Acot2, Cidea, Cox4i1, Cox8b, Dio2, Elovl3, Eva1a, Fabp3,
triglycerides and IL-6 by study end, which were collectively lowered          Ppargc1a, Ppargc1b, Ppara and Prdm16) in vWAT of mice receiving
by X203 therapy to below the levels at 75 weeks of age (Extended Data         anti-IL-11 (Fig. 4d). Age-dependent up-regulation of UCP1 and PGC1α in
Fig. 7d,e). Over the course of the experiment, markers of liver dam-          male mice receiving anti-IL-11 was validated at the protein level (Fig. 4e)
age, hepatic triglyceride content and indexed liver mass increased in            To support our findings, we showed age-related suppression of UCP1
untreated and IgG control mice, whereas these phenotypes were either          expression in vWAT of female control mice, which was mitigated in
improved or reduced in mice receiving X203 (Fig. 3i–k and Extended            female mice lacking Il11 and in mice of both sexes lacking Il11ra1 (Fig. 4f
Data Fig. 7f).                                                                and Extended Data Fig. 9b). A targeted assessment of mitochondrial
   There was a reduction in indexed vWAT and liver mass and an increase       gene expression in vWAT revealed significant increases in terms asso-
in indexed muscle mass in 100-week-old mice receiving X203, compared          ciated with mitochondrial biogenesis and function in mice receiving
with both age-matched controls and 75-week-old mice (Fig. 3k and              anti-IL-11 (Extended Data Fig. 9c,d).
Extended Data Fig. 7g). Mice receiving X203 had diminished scWAT                 In mice receiving X203, there was strong up-regulation of Clstn3b, a
and an increase in BAT (Extended Data Fig. 7h). The age-specific pheno-       newly identified mammal-specific product of the 3′ end of the Clstn3
type of enlarged seminal vesicles in male mice37 was again diminished         locus that promotes WAT triglyceride metabolism in partnership with
by IL-11 loss of function (IgG: 8 out of 13, X203: 2 out of 12; P = 0.022)    S100b42,43, which was also upregulated (Fig. 4g and Extended Data
(Supplementary Table 3).                                                      Fig. 9e). There was limited down-regulation of Ucp1 in BAT with age
   Fibrosis is a canonical feature of ageing and a hallmark of senescence,    in wild-type mice, and Ucp1 expression was mildly increased in BAT of
and IL-11 is known to be pro-fibrotic in human cells and in young adult       Il11−/− mice but not in mice receiving anti-IL-11 (Extended Data Fig. 9f,g).


                                                                                                               Nature | Vol 632 | 1 August 2024 | 161
Article
                   a                                                  Phenotype assessment:                                                                                       b              50
                                                                                                                                                                                                                                                                                           c
                                                                      1. MRI (start + end)
                                                                      2. GTT + ITT (start + end)                                                                                                                                                                                                                          <0.0001




                                                                                                                                                                              Body weight (g)
                                                                                                                                                                                                                                                                                                                                                                                                                    <0.0001
                                                                      3. Grip strength (end)                                                                                                     40                                                                                                       10                                                                             15
                                                                      4. Frailty (start + end)                                                                                                                                                                                                                      0.8660
                                                                                                                                                                                                                                                      0.0023                                                                                                                                                    0.9319




                                                                                                                                                                                                                                                                                                                                                          Δ Lean mass (%)
                                                                      5. Metabolic cage                                                                                                                                                                                                                    5                                                                             10




                                                                                                                                                                                                                                                                                         Δ Fat mass (%)
                                                                      6. Molecular assays (end)                                                                                                  30      Untreated                                                                                         0                                                                                         5
                                                                                                                                                                                                         IgG
                                                                                                                                                                                                         Anti-IL-11                                                                                        –5                                                                                        0
                                                                                                                                                                                                 20
                     40 mg kg–1 IP                                                                                                                                                                     0 3 6 9 12 15 18 21 24 Time (weeks)
                                                                                                                                                                                                                                                                                                          –10                                                                             –5
                   once per 3 weeks                                                                                                                                                                         Variation (%)   P value
                                                                75                                                                     100                                                                                                                                                                –15                                                                 –10
                            Age (weeks)                                                                                                                                                         Interaction     4.241     8.02 × 10–12
                                                                75 weeks                                                                                                                              Time      14.25     6.21 × 10–16
                                                                                                                                                                                                  Antibody      24.79     2.27 × 10–3
                                                                                                                                                                                                   Subject      45.51     3.65 × 10–71
                                                              Untreated           IgG                                 Anti-IL-11

                   d                                          GTT                                                             ITT                                    e                          10
                                                                                                                                                                                                                                          <0.0001                                                                                 f
                                                                                                                            0.0048                                                                                                                                                     Baseline                                                       8                                                     <0.0001
                                                          <0.0001                                                                                                                                                                 0.925
                                             500                                               600                            0.0001                                                                                                                                                   Untreated




                                                                                                                                                                                                                                                                                                                              (g per g body weight)
                                                                                                                                                                                                 8




                                                                                                                                                                                                                                                                                                                                Full body strength
                                                         0.9642                                                           >0.9999                                                                                                                                                      IgG                                                            7




                                                                                                                                                                    Frailty score
                                             250                                               400                                                                                                                                                                                     Anti-IL-11
                      Δ AUC (a.u.)




                                                                                Δ AUC (a.u.)




                                                                                                                                                                                                 6                                                                                                                                                    6
                                                 0                                             200

                                                                                                                                                                                                 4                                                                                                                                                    5
                                             –250                                                           0

                                                                                                                                                                                                 2                                                                                                                                                    4
                                             –500                                              –200
                                                                                                                                                                                                      Untreated                           IgG         Anti-IL-11

    g                                                         Day                                                             Night
                                                                                                                                                                                                              h                                                           i                                                                                                               j
                                                                                                                                                                                                                                                                                                                                                                                                                          0.0359
                   1.00                                                                                                                                      Young                                                                                                                                                   0.0095
                                                                                                                                                                                                                                                                                                                                                                                                                       0.0011
                                                                                                                                                             Old + anti-IL-11                                                               <0.0001                                                               0.0013
                   0.95                                                                                                                                                                                                                                                                                                                                                                                             0.0026
                                                                                                                                                             Old + IgG                                                                                                                                                   <0.0001                                                                                            <0.0001




                                                                                                                                                                                                                                                                                                                                                                            Liver triglyceride (mg g–1)
                                                                                                                                                                                                                             37       0.8110<0.0001                                     200                                                                                                               400
                   0.90                                                                                                                                                                                                                                                                                         0.0002
  RER (VCO2/VO2)




                                                                                                                                                                                                                                                                   Serum ALT (U l–1)
                                                                                                                                                                                                          Temperature (°C)


                                                                                                                                                                                                                                                                                        150                                                                                                               300
                   0.85                                                                                                                                                                                                      36

                   0.80                                                                                                                                                                                                                                                                 100                                                                                                               200
                                                                                                                                                                                                                             35
                   0.75                                                                                                                                                                                                                                                                   50                                                                                                              100

                   0.70                                                                                                                                                                                                      34                                                                 0                                                                                                           0

                   0.65
                                         0           3         6         9        12      15                                  18         21        24
                                                                             Time (hours)

     k                                                        Liver                                                                   vWAT                                                              Gastrocnemius                                 m                                                                                                        100 weeks
                                                              0.0056
                                                                                                                                                                                                                                                                                            75 weeks                                       IgG                                                                  Anti-IL11
                                                       0.0164                                                                       <0.0001                                                                          0.0024                                                                                                                                                                                                     kDa
                              0.08                   0.0478        0.0008                                   0.06                                                                  0.015                                  <0.0001
                                                                                                                                                                                                                                                          IL11                                                                                                                                                                   25
                              0.06                                                                                                                                                                     0.0003
  Organ weight/




                                                                                 Organ weight/




                                                                                                                                                    Organ weight/
   body weight




                                                                                  body weight




                                                                                                                                                     body weight




                                                                                                            0.04                                                                                                                                       p-ERK                                                                                                                                                                     40
                              0.04                                                                                                                                                0.010                                                                                                                                                                                                                                          100
                                                                                                                                                                                                                                                    p-p90RSK
                                                                                                            0.02
                              0.02                                                                                                                                                                                                                    p-LKB1                                                                                                                                                                     50
                                                                                                                      0                                                           0.005                                                                                                                                                                                                                                          70
                                         0                                                                                                                                                                                                            p-AMPK
                                                                                                                                                                                                                 0.0270
     l                                                    0.0422
                                                                                                                                    0.0359
                                                                                                                                                                                                                   <0.0001
                                                                                                                                                                                                                                                      p-MTOR                                                                                                                                                                     260
                                                                                                                                       0.0029                                                                                                                                                                                                                                                                                    100
                                                             0.0004                                                                                                                                                                                 p-p70S6K
                                             5                                                                       10                   0.0001                                                20    0.0009
                                                                0.0001
                    Collagen (μg mg–1)




                                                                                                Collagen (μg mg–1)




                                                                                                                                                                      Collagen (μg mg–1)




                                             4                                                                        8                                                                                                                               p-S6RP
                                                                                                                                                                                                15                                                                                                                                                                                                                               25
                                             3                                                                        6
                                                                                                                                                                                                10                                                        p16                                                                                                                                                                    15
                                             2                                                                        4
                                                                                                                                                                                                 5                                                        p21                                                                                                                                                                    15
                                             1                                                                        2
                                                                                                                                                                                                                                                      GAPDH                                                                                                                                                                      35
                                             0                                                                        0                                                                          0

Fig. 3 | Therapeutic inhibition of IL-11 reduces age-associated metabolic                                                                                                                                                          after IgG or X203 administration was started (n = 10 per group). h–j, Body
dysfunction, pathogenic signalling and sarcopenia in male mice.                                                                                                                                                                    temperatures (h), serum ALT (i) and liver triglycerides ( j). k,l, Indexed
a, Schematic of anti-IL-11 (X203) therapeutic dosing experiment in old male mice                                                                                                                                                   weights of (k) and total collagen content (by hydroxyproline assay) in (l) liver,
for experiments shown in b–m. Mice were either aged naturally (untreated)                                                                                                                                                          gastrocnemius and vWAT. m, Western blot showing activation status of ERK1/2,
or given either X203 or an IgG control antibody (40 mg kg−1, every 3 weeks)                                                                                                                                                        p90RSK, LKB1, AMPK, mTOR, p70S6K, S6RP and protein expression levels of
starting from 75 weeks of age for a duration of 25 weeks. Created with                                                                                                                                                             IL-11, p16, p21 and GAPDH in vWAT (n = 6 per group). Western blots of total protein
BioRender.com. b, Body weights across time. c,d, Changes (Δ) in fat and lean                                                                                                                                                       are presented in Extended Data Fig. 7i. b–d,f,h–l, Data are mean ± s.d. 75-week-old
mass percentage (c) and area under the curve (AUC) of GTT and ITT (d) (values                                                                                                                                                      control: n = 10 (f), n = 14 (i–l); untreated 100-week-old: n = 6 (except for k (liver),
at endpoint (100-week-old) − values at starting point (75-week-old)). a.u.,                                                                                                                                                        n = 5); IgG-treated 100-week-old: n = 13; X203-treated 100-week-old: n = 12. Two-
arbitrary units. e, Frailty scores at start and endpoint. Data are shown as                                                                                                                                                        way repeated measures ANOVA with Sidak’s correction (b); one-way ANOVA
values recorded at starting and endpoint. f, Full body grip strength. g, RER in                                                                                                                                                    with Tukey’s correction (c,d (GTT), e,f,h–l); one-way ANOVA with Kruskal–
young (14-week-old) and IgG or X203-treated old (81-week-old) mice, 6 weeks                                                                                                                                                        Wallis correction (d (ITT)). For gel source data, see Supplementary Fig. 1.



  Pro-inflammatory gene expression was higher in vWAT of mice                                                                                                                                                                      and old Il11ra1−/− and wild-type mice confirmed age-dependent
receiving IgG compared with those receiving X203 (Fig. 4b), mir-                                                                                                                                                                   pro-inflammatory gene expression in the vWAT of wild-type mice that
roring findings seen in livers of Il11ra1−/− mice and vWAT of Il11−/−                                                                                                                                                              was decreased in mice of Il11ra1−/− genotype across sexes (Extended
mice (Extended Data Figs. 2i and 5m). Further analysis of young                                                                                                                                                                    Data Fig. 9h).


162 | Nature | Vol 632 | 1 August 2024
  a                                                                                                                                                                                       b




                                               IL-6–JAK–STAT3 signalling
                                               Oxidative phosphorylation
                                                                                                                                                                                                                                                                                Tissue




                                               TNF signalling via NF-κB
                                                                                                                                                                                                Tissue                                                                             vWAT




                                               Inflammatory response
                                               Xenobiotic metabolism


                                               Fatty acid metabolism




                                               IL-2–STAT5 signalling
                                               Bile acid metabolism
                                                                                                                                                                                              Antibody                                                                             Liver




                                               KRAS signalling UP




                                               Allograft rejection
                                                                                                                                                                                                                                                                                   Gastroc




                                               G2M checkpoint

                                               MYC Targets V1
   FDR                                                                                                                                                                                                                                                           Acod1




                                               IFNα response
                                               Apical junction




                                               Mitotic spindle

                                               IFNγ response
                                                                                                                                                                                                                                                                                Antibody




                                               Adipogenesis
   ≤1.23 × 10–4




                                               Coagulation
                                                                                                                                                                                                                                                                 Tnf
                                               Peroxisome




                                               E2F targets
                                                                                                                                                                                                                                                                                  IgG




                                               Apoptosis
   ≤3.36 × 10–4
                                                                                                                                                                                                                                                                 Parp14           Anti-IL-11
   ≤4.63 × 10–4




                                               EMT
   ≤1.72 × 10–3                                                                                                                                                                                                                                                  Il10           z-score (TPM)
         <0.05                                                                                                                                                                                                                                                   Bst1                3
                                                                                                                               Gastroc:                                                                                                                                              2
                                      2.7                                                                                                                                                                                                                        Il1b
                                                                                                                               Anti-IL-11 vs IgG                                                                                                                                     1
                                                                                                                               Liver:                                                                                                                            Itgam               0
                             NES




                                                                                                                                                                                                                                                                                     −1
                                                                                                                               Anti-IL-11 vs IgG                                                                                                                 Itgax               −2
                                                                                                                               vWAT:                                                                                                                             Cdkn2a              −3
                                     –2.7                                                                                      Anti-IL-11 vs IgG


  c                                                                                            d                           100 weeks                                                                             e
                                                                                                                IgG                                                  Anti-IL-11                                                                                   100 weeks
                                                  1.55 × 10–7
                                      3,000                                                                                                                                                                                              75 weeks               IgG           Anti-IL-11
                                                                                                                                                                                                     Acot2                                                                                     kDa
                                                                                                                                                                                                     Cidea            UCP1                                                                     25
                                                                                                                                                                                                     Cox4i1
                        Ucp1 (TPM)




                                      2,000                                                                                                                                                                                                                                                    140
                                                                                                                                                                                                                     PGC1α
                                                                                                                                                                                                     Cox8b
                                                                                                                                                                                                     Dio2            GAPDH                                                                     35
                                      1,000                                                                                                                                                          Elovl3
                                                                                                                                                                                                     Eva1a
                                            0                                                                                                                                                        Fabp3                    f                  Female
                                                                                                                                                                                                     Ppargc1a
                                                             1




                                       100
                                                 G




                                                                                                                                                                                                                                        2.0
                                                            -1




                                                                                                                                                                                                     Ppargc1b                                             <0.0001
                                                 Ig

                                                        IL




                                     weeks                                                                                                                                                                                                                                     Young Il11+/+
                                                       ti-




                                                                                                                                                                                                     Ppara
                                                      An




                                                                                                                                                                                                                                        1.5                                    Young Il11–/–
                                                                                                                                                                                                     Prdm16




                                                                                                                                                                                                                             Ucp1 RNA
                                                                                                                                                                                                                                                                               Old Il11+/+
                                                                                                                                                                                         log2 (FC)                                      1.0
                                                                                                                                                                                                                                                                               Old Il11–/–
                                                                                                        –2            0        2                            4        6
                                                                                                                                                                                                                                        0.5

     g                                                                                                       h                                                                                                                               0
                                                                                                                                                            100 weeks
                                     1.33 × 10–10                                4.85 × 10–7                                                                                                                                                      Variation (%) P value
                   60                                                      60                                                  IgG                                                   Anti-IL-11                             Interaction               2.637     0.00137
                                                                                                                                                                                                          Ccl2               Genotype                 11.65    4.78 × 10–9
                                                                                                                                                                                                                                   Age                70.43 2.612.61 10–22
   Clstn3b (TPM)




                                                             S100b (TPM)




                   40                                                      40                                                                                                                             Ccl5
                                                                                                                                                                                                          Il6
                                                                                                                                                                                                                                             10 weeks                      105 weeks
                                                                                                                                                                                                          Cd68
                   20                                                      20                                                                                                                             Cd4                           WT            Il11–/–         WT             Il11–/–   kDa
                                                                                                                                                                                                          Ly6c
                                                                                                                                                                                                                     UCP1                                                                      25
                    0                                                       0                                                                                                                             Cd19
                                                                                                                                                                                                                 PGC1α                                                                         140
       100
                                            11




                                                                                                                                                                                              log2 (FC)
                                                                                       11
                                     G




                                                                                                                                                                                                                                                                                               40
                                                                                G




                                                                                                                                                                                                                 GAPDH
                             Ig


                                             -




                                                                                Ig


                                                                                         -
                                          IL




     weeks
                                                                                      IL




                                                                                                                          –6                   –4            –2          0           2
                                         ti-




                                                                                     ti-
                                     An




                                                                                 An




   i                                                                            100 weeks                                                                                <0.0001                          j                                      100 weeks
                                                                                                                                                          5,000
                                                                                                                               Lipid droplet size (μm2)




                                                      IgG                                          Anti-IL-11                                                                                                         IgG                                               Anti-IL-11
                                                                                                                                                          4,000

                                                                                                                                                          3,000

                                                                                                                                                          2,000

                                                                                                                                                          1,000

                                                                                                                                                                0
                                                                                                                                                            100
                                                                                                                                                                                 1
                                                                                                                                                                    G

                                                                                                                                                                               -1
                                                                                                                                                                    Ig




                                                                                                                                                          weeks
                                                                                                                                                                                 L
                                                                                                                                                                        t    i-I
                                                                                                                                                                     An




Fig. 4 | Anti-IL-11 reduces vWAT inflammation and reactivates an                                                                                                               per group). f, Relative expression levels of Ucp1 mRNA (young wild-type, n = 8;
age-repressed thermogenic programme. a–e,g–j, Data for therapeutic                                                                                                             young Il11−/−, n = 9; old wild-type, n = 16; old Il11−/−, n = 18) as well as UCP1 and
experiments in old male mice as shown in Fig. 3a. a, Bubble map showing                                                                                                        PGC1α protein expression (n = 6 per group) in vWAT isolated from young and
hallmark gene set enrichment analysis for differentially expressed genes                                                                                                       old female wild-type and Il11−/− mice. g,h, Abundance of Clstn3b and S100b
in the vWAT, liver and gastrocnemius of mice receiving anti-IL-11 therapy                                                                                                      reads (g) and log 2-transformed fold change heat map of pro-inflammatory
compared with IgG. Colour represents normalized enrichment score (NES);                                                                                                        markers (from RNA-seq) (h) in vWAT. i, Haematoxylin and eosin-stained vWAT
black represents negative NES, indicating down-regulation of the gene set;                                                                                                     (scale bars, 100 µm) and quantification of lipid droplet size (mean of lipid droplet
yellow represents positive NES, suggesting up-regulation. Dot size indicates                                                                                                   area, n = 25 (5 fields per mouse from 5 mice per group)). j, Immunohistochemistry
significance (the larger the dot, the smaller the adjusted P value). EMT, epithelial–                                                                                          staining of CD68 in vWAT (scale bars, 50 µm). a–d,f–h, Liver and gastrocnemius
mesenchymal transition. b, Heat map of row-wise scaled transcripts per million                                                                                                 (n = 8 per group), vWAT IgG, n = 7; vWAT anti-IL-11, n = 6. c,f,g,i, Data are
(TPM) values of senescence genes in vWAT, liver, gastrocnemius. c, Abundance                                                                                                   mean ± s.d. Two-tailed Student’s t-test (c,g,i); two-way ANOVA with Sidak’s
of Ucp1 reads in vWAT. d, log 2-transformed fold change heat map of beiging                                                                                                    correction (f). For gel source data, see Supplementary Fig. 1. Scale bars:
genes in vWAT from IgG- or anti-IL-11-treated 100-week-old mice, based on                                                                                                      100 μm (i), 50 μm ( j).
RNA-seq. e, Western blot of UCP1, PGC1α and GAPDH expression in vWAT (n = 6


  Stromal inflammation is associated with immune cell infiltration,                                                                                                            (Fig. 4h). Histology studies revealed that vWAT of X203-treated mice
and we found that the immune cell surface marker genes Cd68, Cd4,                                                                                                              exhibited an average 2.5-fold reduction in lipid droplet area, increased
Ly6C and Cd19 were downregulated in the vWAT of mice receiving X203                                                                                                            beige adipocyte foci and fewer resident CD68+ macrophages (Fig. 4i,j).


                                                                                                                                                                                                                            Nature | Vol 632 | 1 August 2024 | 163
Article
  a                                                                          b                                                                               c
                        1.0                                                                      1.0                                                                             1.0
  Cumulative survival




                                                                           Cumulative survival
                        0.8                                                                      0.8                                                                             0.8




                                                                                                                                                           Cumulative survival
     probability




                                                                              probability




                                                                                                                                                              probability
                        0.6                                                                      0.6                                                                             0.6

                        0.4        Il11–/– (n = 34)                                              0.4        Il11–/– (n = 37)                                                     0.4        Il11–/– (n = 71)
                                   WT (n = 41)                                                              WT (n = 49)                                                                     WT (n = 90)
                        0.2                                                                      0.2                                                                             0.2
                              log rank P = 4.69 × 10–5                                                 log rank P = 2.01 × 10–8                                                        log rank P = 5.78 × 10–11
                        0.0   Wilcoxon P = 4.70 × 10–5                                             0   Wilcoxon P = 7.28 × 10–7                                                    0   Wilcoxon P = 2.80 × 10–10
                               0   20 40       60 80 100 120 140 160 180                                0    20   40    60 80 100 120 140 160 180                                       0   20 40      60 80 100 120 140 160 180
                                                Age (weeks)                                                              Age (weeks)                                                                    Age (weeks)

  d                                                                          e                                                                               f
                        1.0                                                                      1.0                                                                             1.0
  Cumulative survival




                                                                           Cumulative survival




                                                                                                                                                           Cumulative survival
                        0.8                                                                      0.8                                                                             0.8
     probability




                                                                              probability




                                                                                                                                                              probability
                        0.6                                                                      0.6                                                                             0.6

                        0.4        Anti-IL-11 (n = 24)                                           0.4       Anti-IL-11 (n = 13)                                                   0.4       Anti-IL-11 (n = 37)
                                   IgG (n = 25)                                                            IgG (n = 13)                                                          0.2       IgG (n = 38)
                        0.2                                                                      0.2
                              log rank P = 7.61 × 10–5                                                 log rank P = 9.30 × 10–6                                                        log rank P = 2.41 × 10–8
                         0    Wilcoxon P = 2.25 × 10–4                                            0    Wilcoxon P = 5.56 × 10–5                                                   0    Wilcoxon P = 1.06 × 10–7

                              0    20   40    60 80 100 120 140 160 180                                0    20    40   60 80 100 120 140 160 180                                       0    20   40   60       80 100 120 140 160 180
                                               Age (weeks)                                                              Age (weeks)                                                                     Age (weeks)

Fig. 5 | Genetic or pharmacologic inhibition of IL-11 extends life expectancy                                                  female (e) and sex-pooled (f) mice, comparing those receiving monthly
of male and female mice. a–c, Kaplan–Meier survival curves (shading represents                                                 administration of IgG or X203 (40 mg kg−1, intraperitoneal injection), starting
95% confidence interval) showing the cumulative survival probabilities for                                                     from 75 weeks of age (red dotted line). Statistical significance (two-tailed
male (a), female (b) and sex-pooled (c) wild-type and Il11−/− mice. d–f, Kaplan–                                               P value) was assessed by means of the log-rank (Mantel–Cox) and Wilcoxon
Meier survival curves showing the cumulative survival probabilities for male (d),                                              test for survival curve comparisons.



                                                                                                                               thought to be important for ageing, however SNPs at the IL11 locus are
Inhibition of IL-11 extends lifespan                                                                                           associated with osteoarthritis45 and menopause46, and IL-11 is linked
In parallel to the healthspan experiments, we carried out lifespan stud-                                                       with senescence and diseases that are common in older people22,27.
ies in male and female Il11−/− mice and wild-type littermate controls,                                                             The metabolic effects seen with inhibition of IL-11 in old mice phe-
which we observed until they were found dead or euthanized when                                                                nocopy those of young mice with WAT-specific deletion of Raptor41.
moribund (Fig. 5a–c). Pooled analysis showed that Il11−/− mice had                                                             Although we did not study mice at thermoneutrality, we surmise
significantly longer lifespans than wild-type controls (median lifes-                                                          that inhibition of IL-11 prevents mTORC1 activation in fat, afford-
pan: wild-type, 120.9 weeks; Il11−/−, 151 weeks). Sex-specific analyses                                                        ing age-repressed WAT beiging that can be particularly prominent
revealed significant lifespan extension in female Il11−/− (median lifespan:                                                    in mice40,41. We highlight that although we excluded food intake and
wild-type, 118.9 weeks; Il11−/−, 148.3 weeks) as well as male Il11−/− (median                                                  enteric or locomotor-related energy expenditure and showed WAT
lifespan: wild-type, 128.7 weeks; Il11−/−, to be determined) mice.                                                             beiging across genetic and therapeutic models, we did not pinpoint
   To progress our studies to a more translationally relevant approach,                                                        the specific physiology leading to weight loss with IL-11 inhibition.
we examined the effects on lifespan following IL-11 inhibition in late life                                                        Beyond metabolism, inhibition of IL-11 improved deterministic fea-
using 75-week-old male and female mice assigned to receive monthly                                                             tures of ageing that are common among vertebrates (such as frailty and
injections of either anti-IL-11 or IgG until death (Fig. 5d–f and Extended                                                     sarcopenia), showing generic anti-ageing benefits at the organismal
Data Fig. 10). Pooled analysis showed that mice receiving anti-IL-11 have                                                      level. Intriguingly, some of the beneficial effects of germline Il11ra1 or
significantly longer lifespans (median lifespan: IgG, 120.9 weeks; X203,                                                       Il11 deletion, notably in muscle and fat, were apparent even in young
155.6 weeks). Sex-specific analyses showed a significant extension                                                             mice, perhaps suggesting primacy of metabolic benefits. We did not
of lifespan in females (median lifespan: IgG, 117.1 weeks; X203, 146.4                                                         discern cell-type specificity but infer that tissue-localized IL-11 activ-
weeks), which was also apparent for males (median lifespan: wild-type,                                                         ity is important, given its known autocrine and paracrine activities22.
130.3 weeks; X203, 159.6 weeks).                                                                                                   Inhibition of IL-11 increased lifespan in both male and female mice.
   Cancers are a common cause of death in old mice44, and gross autopsy                                                        The magnitude of lifespan extension remains to be fully determined but
data revealed fewer macroscopic tumours in mice with Il11 deletion                                                             current data suggest that anti-IL-11 therapy given in late life increases
(pooled sexes: wild-type, 49 out of 84 mice had tumours; Il11−/−, 3 out                                                        median lifespan by more than 20% in both sexes. In these experiments,
of 25 mice had tumours; P < 0.0001) or on anti-IL-11 therapy (pooled                                                           anti-IL-11 was injected in mice from 75 weeks of age (human equivalent to
sexes: IgG, 22 out of 36 mice had tumours; X203, 3 out of 19 mice had                                                          approximately 55 years of age) and it remains to be seen whether admin-
tumours; P = 0.0013) (Supplementary Tables 6 and 7).                                                                           istration to older mice has similar effects and/or if short term anti-IL-11
                                                                                                                               therapy is effective for lifespan extension, as seen for rapamycin. Mouse
                                                                                                                               mortality in old age is often cancer-related44 and our end-of-life autopsy
Discussion                                                                                                                     data support the notion that inhibition of IL-11 significantly reduces
IL-11 is progressively upregulated across tissues with age, probably as an                                                     age-related cancers. Of note, IL-11 is important for tumorigenesis and
alarmin-type response to age-related pathogenic factors that include                                                           tumour immune evasion and clinical trials of anti-IL-11 in combination
cytokines, proteotoxic stress, oxidative species and DNA damage,                                                               with immunotherapy to treat cancer are planned22.
among others22. We propose that the pleiotropic benefits seen with inhi-                                                           Chronic sterile inflammation is an important hallmark of ageing that
bition of IL-11 reflect its modulation of multiple ageing pathways (such                                                       is intimately linked with senescence and implicated in the pathogenesis
as ERK, AMPK, mTOR and JAK–STAT3), as seen using polypharmacy in                                                               of age-related frailty, metabolic dysfunction and multi-morbidity7,16,17,39.
flies2,6. IL-11 has not been extensively studied and was not previously                                                        Studies of invertebrates have shown that innate immune signalling,


164 | Nature | Vol 632 | 1 August 2024
notably Jak–Stat signalling in fly adipose tissue, can adversely affect                               21.   Xu, M. et al. JAK inhibition alleviates the cellular senescence-associated secretory
                                                                                                            phenotype and frailty in old age. Proc. Natl Acad. Sci. USA 112, E6301–E6310 (2015).
metabolism and lifespan47,48. We show here that a pro-inflammatory                                    22.   Cook, S. A. Understanding interleukin 11 as a disease gene and therapeutic target.
cytokine can affect affect age-related decline and lifespan in a mammal.                                    Biochem. J. 480, 1987–2008 (2023).
The relative contributions of canonical ( JAK–STAT3) and non-canonical                                23.   Widjaja, A. A. et al. IL11 stimulates ERK/P90RSK to inhibit LKB1/AMPK and activate mTOR
                                                                                                            initiating a mesenchymal program in stromal, epithelial, and cancer cells. iScience 25,
(MEK–ERK) IL-11 signalling, alone or in combination, for ageing phe-                                        104806 (2022).
notypes remain to be determined.                                                                      24.   Widjaja, A. A. et al. IL11 stimulates IL33 expression and proinflammatory fibroblast
  Inhibition of ERK or mTOR or activation of AMPK by trametinib, rapa-                                      activation across tissues. Int. J. Mol. Sci. 23, 8900 (2022).
                                                                                                      25.   Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110–115
mycin or metformin, respectively, increase lifespan in model organisms                                      (2017).
and such drugs are advocated by some for use in humans. However,                                      26.   Pinti, M. et al. A comprehensive analysis of cytokine network in centenarians. Int. J. Mol.
these agents have on- and off-target toxicities along with variable, and                                    Sci. 24, 2719 (2023).
                                                                                                      27.   Chen, H. et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated
sometimes detrimental, effects on healthspan and inflammation12,13,35,49.                                   pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency.
Our data suggest that anti-IL-11 therapy, which has a reassuring safety                                     Exp. Mol. Med. 52, 130–151 (2020).
profile and is currently in early-stage clinical trials for fibroinflam-                              28.   Tabula Muris Consortium. A single-cell transcriptomic atlas characterizes ageing tissues
                                                                                                            in the mouse. Nature 583, 590–595 (2020).
matory diseases, is a potentially translatable approach for extending                                 29.   Widjaja, A. A. et al. Redefining IL11 as a regeneration-limiting hepatotoxin and therapeutic
human healthspan and lifespan22.                                                                            target in acetaminophen-induced liver injury. Sci. Transl. Med. 13, eaba8146 (2021).
                                                                                                      30.   Nandurkar, H. H. et al. Adult mice with targeted mutation of the interleukin-11 receptor
                                                                                                            (IL11Ra) display normal hematopoiesis. Blood 90, 2148–2159 (1997).
                                                                                                      31.   Ng, B. et al. Similarities and differences between IL11 and IL11RA1 knockout mice for lung
Online content                                                                                              fibro-inflammation, fertility and craniosynostosis. Sci. Rep. 11, 14088 (2021).
Any methods, additional references, Nature Portfolio reporting summa-                                 32.   Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory
                                                                                                            of ageing. Nat. Rev. Genet. 19, 371–384 (2018).
ries, source data, extended data, supplementary information, acknowl-                                 33.   Herranz, N. et al. mTOR regulates MAPKAPK2 translation to control the senescence-
edgements, peer review information; details of author contributions                                         associated secretory phenotype. Nat. Cell Biol. 17, 1205–1217 (2015).
and competing interests; and statements of data and code availability                                 34.   Campisi, J. Replicative senescence: an old lives’ tale? Cell 84, 497–500 (1996).
                                                                                                      35.   Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and
are available at https://doi.org/10.1038/s41586-024-07701-9.                                                Akt/PKB. Mol. Cell 22, 159–168 (2006).
                                                                                                      36.   Kelley, D. E. & Mandarino, L. J. Fuel selection in human skeletal muscle in insulin resistance:
                                                                                                            a reexamination. Diabetes 49, 677–683 (2000).
1.  López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging:       37.   Finch, C. E. & Girgis, F. G. Enlarged seminal vesicles of senescent C57BL-6J mice. J. Gerontol.
    an expanding universe. Cell 186, 243–278 (2022).                                                        29, 134–138 (1974).
2.  Fabian, D. K., Fuentealba, M., Dönertaş, H. M., Partridge, L. & Thornton, J. M. Functional        38.   Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver
    conservation in genes and pathways linking ageing and immunity. Immun. Ageing 18, 23                    fibrosis, inflammation, and steatosis in mouse models of non-alcoholic steatohepatitis.
    (2021).                                                                                                 Gastroenterology 157, 777–792.e14 (2019).
3.  Selman, C. et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.          39.   Moiseeva, V. et al. Senescence atlas reveals an aged-like inflamed niche that blunts
    Science 326, 140–144 (2009).                                                                            muscle regeneration. Nature 613, 169–178 (2022).
4. Salminen, A. & Kaarniranta, K. AMP-activated protein kinase (AMPK) controls the aging              40.   Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and
    process via an integrated signaling network. Ageing Res. Rev. 11, 230–241 (2012).                       human. Cell 150, 366–376 (2012).
5.  Slack, C. et al. The Ras–Erk–ETS-signaling pathway is a drug target for longevity. Cell 162,      41.   Polak, P. et al. Adipose-specific knockout of raptor results in lean mice with enhanced
    72–83 (2015).                                                                                           mitochondrial respiration. Cell Metab. 8, 399–410 (2008).
6.  Castillo-Quan, J. I. et al. A triple drug combination targeting components of the nutrient-       42.   Zeng, X. et al. Innervation of thermogenic adipose tissue via a calsyntenin 3β-S100b axis.
    sensing network maximizes longevity. Proc. Natl Acad. Sci. USA 116, 20817–20819 (2019).                 Nature 569, 229–235 (2019).
7.  Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat.      43.   Qian, K. et al. CLSTN3β enforces adipocyte multilocularity to facilitate lipid utilization.
    Med. 25, 1822–1832 (2019).                                                                              Nature 613, 160–168 (2023).
8.  Rogers, N. H., Landa, A., Park, S. & Smith, R. G. Aging leads to a programmed loss of brown       44.   Lipman, R., Galecki, A., Burke, D. T. & Miller, R. A. Genetic loci that influence cause of
    adipocytes in murine subcutaneous white adipose tissue. Aging Cell 11, 1074–1083 (2012).                death in a heterogeneous mouse stock. J. Gerontol. A 59, 977–983 (2004).
9.  Gonçalves, L. F. et al. Ageing is associated with brown adipose tissue remodelling and            45.   Tachmazidou, I. et al. Identification of new therapeutic targets for osteoarthritis through
    loss of white fat browning in female C57BL/6 mice. Int. J. Exp. Pathol. 98, 100–108 (2017).             genome-wide analyses of UK Biobank data. Nat. Genet. 51, 230–236 (2019).
10. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically                 46.   Kichaev, G. et al. Leveraging polygenic functional enrichment to improve GWAS power.
    heterogeneous mice. Nature 460, 392–395 (2009).                                                         Am. J. Hum. Genet. 104, 65–75 (2019).
11. Miller, R. A. et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent       47.   Sung, E. J. et al. Cytokine signaling through Drosophila Mthl10 ties lifespan to
    and metabolically distinct from dietary restriction. Aging Cell 13, 468–477 (2014).                     environmental stress. Proc. Natl Acad. Sci. USA 114, 13786–13791 (2017).
12. Bansal, A., Zhu, L. J., Yen, K. & Tissenbaum, H. A. Uncoupling lifespan and healthspan in         48.   Lourido, F., Quenti, D., Salgado-Canales, D. & Tobar, N. Domeless receptor loss in fat body
    Caenorhabditis elegans longevity mutants. Proc. Natl Acad. Sci. USA 112, E277–E286                      tissue reverts insulin resistance induced by a high-sugar diet in Drosophila melanogaster.
    (2015).                                                                                                 Sci. Rep. 11, 3263 (2021).
13. Willows, J. W. et al. Age-related changes to adipose tissue and peripheral neuropathy in          49.   Correia-Melo, C. et al. Rapamycin improves healthspan but not inflammaging in Nfkb1−/−
    genetically diverse HET3 mice differ by sex and are not mitigated by rapamycin longevity                mice. Aging Cell 18, e12882 (2019).
    treatment. Aging Cell 22, e13784 (2023).
14. Garmany, A., Yamada, S. & Terzic, A. Longevity leap: mind the healthspan gap. NPJ Regen.
                                                                                                      Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
    Med. 6, 57 (2021).
                                                                                                      published maps and institutional affiliations.
15. Sukoff Rizzo, S. J. et al. Assessing healthspan and lifespan measures in aging mice:
    optimization of testing protocols, replicability, and rater reliability. Curr. Protoc. Mouse
    Biol. 8, e45 (2018).                                                                                                 Open Access This article is licensed under a Creative Commons Attribution
16. Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal                          4.0 International License, which permits use, sharing, adaptation, distribution
    Transduct. Target. Ther. 8, 239 (2023).                                                                              and reproduction in any medium or format, as long as you give appropriate
17. Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular           credit to the original author(s) and the source, provide a link to the Creative Commons licence,
    disease, and frailty. Nat. Rev. Cardiol. 15, 505–522 (2018).                                      and indicate if changes were made. The images or other third party material in this article are
18. Puzianowska-Kuźnicka, M. et al. Interleukin-6 and C-reactive protein, successful aging,           included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
    and mortality: the PolSenior study. Immun. Ageing 13, 21 (2016).                                  to the material. If material is not included in the article’s Creative Commons licence and your
19. Thomas, R., Wang, W. & Su, D.-M. Contributions of age-related thymic involution to                intended use is not permitted by statutory regulation or exceeds the permitted use, you will
    immunosenescence and inflammaging. Immun. Ageing 17, 2 (2020).                                    need to obtain permission directly from the copyright holder. To view a copy of this licence,
20. O’Brown, Z. K., Van Nostrand, E. L., Higgins, J. P. & Kim, S. K. The inflammatory transcription   visit http://creativecommons.org/licenses/by/4.0/.
    factors NFκB, STAT1 and STAT3 drive age-associated transcriptional changes in the human
    kidney. PLoS Genet. 11, e1005734 (2015).                                                          © The Author(s) 2024




                                                                                                                                                  Nature | Vol 632 | 1 August 2024 | 165
Article
Methods
                                                                           Cell culture
Antibodies                                                                 Cells were grown and maintained at 37 °C and 5% CO2.The growth
Commercial antibodies. Adiponectin (AdipoQ, 21613-1-AP, Protein-           medium was renewed every 2–3 days and cells were passaged at 80%
tech), p-AMPK Thr172 (2535, clone 40H9, CST), AMPK (5832, clone            confluence, using standard trypsinization techniques. All experi-
D63G4, CST), CD31 (ab222783, clone EPR17260-263, abcam), CD68              ments were carried out at P3, unless otherwise specified. Cells were
(ab125212, abcam), cyclin D1 (55506, clone E3P5S, CST), p-ERK1/2           serum-starved overnight in basal media prior to stimulation with dif-
Thr202/Tyr204 (4370, clone D13.14.4E, CST), ERK1/2 (4695, clone            ferent treatment conditions (in the absence or presence of antibod-
137F5, CST), GAPDH (2118, clone 14C10, CST), FHL1 (10991-1-AP, Pro-        ies or inhibitors) and durations, as outlined in the main text or figure
teintech), GFP (ab290 and ab6673, abcam), p-LKB1 Ser428 (3482, clone       legends. All commercial cell lines were characterized by the company
C67A3, CST), LKB1 (3047, clone D60C5, CST), p-mTOR Ser2448 (2971,          based on their morphology and by using immunofluorescence for
CST), mTOR (2972,CST), p-NF-κB p65 Ser536 (3033, clone 93H1, CST),         cell-specific markers, as detailed in the respective product datasheet
NF-κB p65 (8242, clone D14E12, CST), p16 (human, ab108349, clone           and certificate of analysis. Potential biological contaminants for
EPR1473, abcam), p16 (mouse, ab232402, clone EPR20418, abcam), p21         HIV-1, HBV, HCV, mycoplasma, bacteria, yeast and fungi were confirmed
(human, ab109520, clone EPR362, abcam), p21 (mouse, ab188224, clone        negative as outlined in the certificate of analysis.
EPR18021, abcam), p-p70S6K Thr389 (9234, clone 108D2, CST), p70S6K
(2708, clone 49D7, CST), p-p90RSK Ser380 (11989, clone D3H11, CST),        Primary human cardiac fibroblasts. Primary human cardiac fibro-
p90RSK (9355, clone 32D7, CST), PDGFRα (AF1062, R&D systems), p-S6         blasts (HCFs) (52-year-old male, 6330, lot 9580, ScienCell) were authen-
ribosomal protein Ser235/236 (4858, clone D57.2.2E, CST), S6 ribosomal     ticated by their fibroblast morphology and phenotype, characterized
protein (2217, clone 5G10, CST), PCNA (13110, clone D3H8P, CST), PGC1α     by immunofluorescence staining for fibronectin and vimentin. Cell
(ab191838, abcam), SLC10A1 (MBS177905, MyBioSource), SM22α                 were grown and maintained in complete fibroblasts medium-2 (2331,
(ab14106, abcam), p-STAT3 Tyr705 (4113, clone M9C6, CST), STAT3            ScienCell) supplemented with 5% foetal bovine serum (FBS, 0500,
(4904, clone 79D7, CST), UCP1 (72298, clone E9Z2V, CST), anti-rabbit       ScienCell), 1% fibroblasts growth supplement-2 (FGS-2, 2382, ScienCell)
horseradish peroxidase (HRP) (7074, CST), anti-mouse HRP (7076,            and 1% penicillin-streptomycin (P/S, 0513, ScienCell). For replicative
CST), anti-rabbit Alexa Fluor 488 (ab150077, abcam), anti-goat Alexa       senescence study, primary HCFs were serially passaged (from P4 to P14)
Fluor 488 (ab150129, abcam) and anti-rabbit Alexa Fluor 555 (ab150074,     in the absence or presence of a neutralizing IL11RA antibody (X209) or
abcam). All commercially available antibodies have been validated          an IgG isotype control (11E10).
by their manufacturer as indicated in their respective datasheet and/
or website.                                                                Primary human hepatocytes. Primary human hepatocytes were iso-
                                                                           lated from a 22-week-old foetus (5200, lot 34967, ScienCell) and authen-
Custom-made antibodies. IgG (clone 11E10), anti-IL-11 (clone X203          ticated by their hepatocyte morphology and phenotype, characterized
for western blot and neutralizing studies), anti-IL11RA (clone X209        by positive immunofluorescence for cytokeratin-18 and western blot
for neutralizing study) were manufactured by Genovac. The suitability      for albumin. Following recovery from the initial thaw cycle, hepatocytes
of IgG (11E10) as a control antibody was validated previously29. X203      were seeded at a density 4 × 105 cells per well of a collagen-coated 6-well
was validated for neutralization of human and mouse IL-1129,38 and for     plate and maintained in hepatocyte medium (5201, ScienCell) which
western blot38,50. X209 was validated previously for neutralization of     contains 2% FBS and 1% penicillin-streptomycin. Hepatocytes were
human and mouse IL11RA38 and for western blot38.                           then used directly for downstream experiments within 48 h of seeding.

Recombinant proteins                                                       Olink proximity extension assay
Recombinant human IL-11 (hIL11, Z03108, Genscript).                        Human hepatocytes were seeded at a density of 2.5 × 105 cells per well
                                                                           into 6-well plates. The culture supernatants were collected following
Chemicals                                                                  stimulation with IL-11 (0, 6 and 24 h) and were sent to Olink Proteomics
Bovine serum albumin (BSA, A7906, Sigma), 16% formaldehyde (w/v),          for proximity extension assays using the 92-protein inflammation panel.
methanol-free (28908, Thermo Fisher Scientific), DAPI (D1306, Thermo       Zero-hour time points refer to time-matched, unstimulated controls
Fisher Scientific), DMSO (D2650, Sigma), rapamycin, (9904, CST),           that were cultured and collected in parallel with the other stated time
Triton X-100 (T8787, Sigma), Tween-20 (170-6531, Bio-Rad) and U0126        points. In this experiment, IL-11 was added at different times to stimulate
(9903, CST),                                                               cells; for instance, at 15:00 on day 1 for the 24-h time point and at 09:00
                                                                           on day 2 for the 6-h time point. Supernatants from the unstimulated
Ethics statements                                                          control, 6 and 24-h time points were collected at the same time. The
All experimental protocols involving human subjects (commercial            protein concentrations were expressed as normalized protein expres-
primary human cell lines) were performed in accordance with the ICH        sion (NPX; log2 scale) and those proteins with concentrations below
Guidelines for Good Clinical Practice. All participants provided written   the limit of detection were excluded from analysis.
informed consent and ethical approvals have been obtained by the
relevant parties as written in the datasheets provided by ScienCell        Operetta high throughput phenotyping assay
from which primary human cardiac fibroblasts and primary human             HCFs (P4, P7, P10 and P14) were seeded in 96-well black CellCarrier
hepatocytes were commercially sourced.                                     plates (PerkinElmer) at a density of 6 × 103 cells per well either untreated
   Animal studies were carried out in compliance with the recommen-        or in the presence of IgG or X209. After reaching ~80% confluence, cells
dations in the Guidelines on the Care and Use of Animals for Scientific    were fixed in 4% formaldehyde, and permeabilized with 0.1% Triton
Purposes of the National Advisory Committee for Laboratory Animal          X-100. Non-specific sites were blocked with blocking solutions (0.5%
Research (NACLAR). All experimental procedures were approved               BSA and 0.1% Tween-20 in PBS). Cells were incubated overnight (4 °C)
(SHS/2019/1481 and SHS/2019/1483) and conducted in accordance              with primary antibodies (p16 and p21) at a dilution of 1:500, followed by
with the SingHealth Institutional Animal Care and Use Committee            incubation with the appropriate Alexa Fluor 488 secondary antibodies
(IACUC). Certified veterinarians were responsible for all animal experi-   (1:1,000, 1 h, room temperature). Cells were then counterstained with
ment procedures according to the laws governing animal research in         1 µg ml−1 DAPI in blocking solution. Antibodies and DAPI were diluted in
Singapore.                                                                 blocking solutions. Each condition was imaged from duplicated wells
and a minimum of seven fields per well using Operetta high-content            an experienced veterinarian, as needed. The principal experimental
imaging system 1483 (PerkinElmer). The measurement of p16 and p21             endpoint was age of death, which was recorded when mice were found
fluorescence intensity per area (normalized to the number of cells)           dead or at the time of euthanasia if they were deemed severely mori-
was performed with Columbus 2.9 (PerkinElmer).                                bund (or unlikely to survive longer than 48 h) at the time of inspection,
                                                                              according to previously described criteria10. Mice with gross tumours,
Seahorse assay                                                                when present, were monitored for tumour progression and euthanized
Primary HCFs were seeded into the Seahorse XF 96-well Cell Culture            when tumours developed >1.5 cm in size (at largest dimension) or when
Microplate (40 × 103 cells per well) and serum-starved overnight prior        tumours become ulcerated, infected or interfered with mobility as per-
to stimulations. Seahorse measurements were performed on Seahorse             mitted by the local SingHealth IACUC. These limits were not exceeded
XFe96 Extracellular Flux Analyzer (Agilent). XF Cell Mito Stress Test kit     in any of the experiments. Gross examination was conducted at autopsy
(103015-100, Agilent) and Seahorse XF Mito Fuel Flex Test kit (103260-        following natural death or euthanasia of mice to observe and document
100, Agilent) were used according to the manufacturer’s protocol to           the presence of visible tumours in the larger body organs and to record
measure the mitochondrial oxygen consumption rate and the percent-            any noticeable gross appearances.
age of fatty acid oxidation, respectively as described previously51. Sea-
horse Wave Desktop software (Ver 2.6.3) was used for report generation        GTT and ITT
and data analysis.                                                            Mice were fasted for 6 h prior to baseline blood glucose measurement.
                                                                              For GTT, mice were injected intraperitoneally with 20% glucose at 2 mg
Animal models                                                                 per g lean mass. For ITT, mice were injected intraperitoneally with
All mice were housed at 21–24 °C with 40–70% humidity on a 12-h light/        recombinant human insulin at 1.2 mU per g body weight. Both glucose
dark cycle and provided food and water ad libitum. Our mouse colonies         and insulin were diluted in sterile DPBS. Blood glucose concentrations
hold specific pathogen free (SPF) status and undergo quarterly and            were then measured at 15, 30, 60, 75 and 90 min after glucose or insulin
annual tests for common pathogens. The room housing our animals               administration for GTT or ITT, respectively. Blood was collected via
is positive for murine norovirus and Helicobacter, and these particular       tail snip and Accu-Chek blood glucometer was used for blood glucose
pathogens are deemed acceptable within our SPF facility. Sample sizes         measurements.
were determined based on the authors’ experience with the prelimi-
nary studies and by referencing a healthspan/lifespan study in mice52         Echo MRI
to detect a 20% change in phenotype between treatment groups or               Mouse body composition (total body fat and lean mass measure-
genotypes with 80% power (α = 0.05). Sample sizes for experiments             ments) was performed 1 day prior to GTT/ITT or euthanasia by Echo
involving Il11ra1−/− and Il11−/− mice (and their respective wild-type mice)   MRI analysis using 4in1 Composition Analyzer for live small animals
varied depending on animal availability. Mice were randomly allocated         (Echo Medical Systems).
to experimental groups on the day of the treatment except for Il11ra1−/−
and Il11−/− in which randomization was not applicable. Treatments or          Frailty scoring
genotypes were not disclosed to investigators generating quantitative         Frailty scoring was performed, with observers blinded to treatment,
readouts during data collection but were revealed during the analysis.        at the start of the experiment or 1–2 days prior to euthanasia using a
The mouse strains used in our study are described below.                      27-point frailty scoring system15. Body temperatures were recorded by
                                                                              rectal thermometry using Kimo Thermocouple Thermometer (TK110,
Il11ra1-deleted mice. Male and female Il11ra1+/+ (wild-type) and Il11ra1−/−   Kimo).
mice25 (B6.129S1-Il11ratm1Wehi/J, The Jackson Laboratory) were euthanized
at 110 weeks of age for blood and tissue collection; 10–12 weeks old male     Grip strength assessment
and female mice of the respective genotypes were used as controls.            A digital grip strength meter (BIO-GS3, BIOSEB) was used to measure
                                                                              full body (4 limbs) and forelimb (both forepaws) grip strengths, as
Il11-deleted mice. Male and female mice lacking functional alleles for        per the manufacturer’s instruction. Mice were allowed to rest for at
Il11 (Il11−/−), which were generated and characterized previously31,50, and   least 1 h between the two tests. The average of 3 readings of maximal
their wild-type counterparts were euthanized at 10–12 weeks of age            average force exerted by each mouse on the grip strength meter was
(young controls) and 104–108 weeks of age (old mice).                         used for analysis.

Il11-EGFP reporter mice. Young (10-week-old) and old (100-week-old)           Measurement of whole-body metabolic parameters
transgenic mice (C57BL/6 J background) with EGFP knocked into the             Whole-body metabolic parameters for IgG and X203-treated (anti-
Il11 gene (Il11-EGFP mice, Cyagen Biosciences)29 were euthanized for          bodycohort), and wild-type and IL-11-knockout (KO cohort) mice
immunofluorescence staining studies of liver, gastrocnemius and               were assessed by open-circuit indirect calorimetry. Animals were
vWAT. Old wild-type littermates were used as aged negative controls.          single-housed in the PhenoMaster automated home-cage system
                                                                              (TSE Systems) at a temperature of 22°C and in a humidity-controlled
In vivo administration of anti-IL-11. Male and female C57BL/6 J mice          environment with a 12-h light/dark cycle. Parameters including oxygen
( Jackson Laboratory) were randomized prior to receiving either no            consumption (VO2), carbon dioxide production (VCO2), food intake,
treatment, anti-IL-11 (X203) or IgG (11E10). X203 or 11E10 (40 mg kg−1,       and locomotor activity were measured simultaneously at 1-min time
every 3 weeks) were administered by intraperitoneal injection, start-         intervals. RER was calculated using the VCO2/VO2 ratio. Locomotor
ing from 75 weeks of age for a duration of 25 weeks; mice were then           activity was divided into horizontal plane locomotor activities, defined
euthanized at 100 weeks of age.                                               as the total number of infrared beam breaks in the x and y axis (counts).
                                                                              Mice were monitored for 5 consecutive overnight periods including
Lifespan studies                                                              an acclimatization period during the first light/dark cycle (day 0–1),
Lifespan studies involved two distinct experimental groups (male and          which was not used for analysis. For both antibody and KO cohorts,
female) (1) C57BL/6 J mice ( Jackson Laboratory) aged 75 weeks that           the control (IgG or wild-type) group (n = 10) and intervention (X203 or
received monthly injections of either anti-IL-11 (X203) or IgG (11E10)        IL-11-knockout) group (n = 10) were divided equally into two consecu-
at a dosage of 40 mg kg−1; and (2) wild-type and Il11−/− mice. Mice were      tive monitoring sessions. Baseline RER comparison was made using
inspected daily and medicated for non-life-threatening conditions by          measurements from the second light/dark cycle (day 1–2). Animals were
Article
given ad libitum access to food and water except during test phases
introduced after day 2 where food access was restricted to assess the      Telomere length and mitochondrial copy number quantification
resting metabolic rate (measured at thermoneutrality (28°C)) and           DNA from HCFs (P4 and P14) and snap-frozen liver, gastrocnemius,
adaptation to fasting (12 h).                                              and vWAT was extracted with the E.Z.N.A. Tissue DNA Kit (D3396-02,
                                                                           Omega Bio-tek) according to the manufacturer’s protocol. Telomere
Bomb calorimetry                                                           length and mitochondrial copy number for HCFs were evaluated by
To measure energy content in mouse stool, bomb calorimetry was             quantitative PCR with reverse transcription (RT–qPCR) with the Rela-
performed by the core service at Department of Food Science and            tive Human Telomere Length Quantification qPCR Assay Kit (8908,
Technology, National University of Singapore. All faecal samples were      ScienCell) and Relative Human Mitochondrial DNA copy number Length
collected and stored at −80 °C prior to measurement. Approximately         Quantification qPCR Assay Kit (8938, ScienCell), respectively. Similarly,
0.9 g of faecal samples were placed into a combustion bag in which a       the telomere length and mitochondrial copy number for mouse tissues
cotton thread and benzoic acid tablets were used as combustion aid.        were evaluated by RT–qPCR with the Relative Mouse Telomere Length
The gross calorie content was then determined using the IKA C5003          Quantification qPCR Assay Kit (M8908, ScienCell) and Relative Human
Control bomb calorimeter on the isoperibolic mode, with C5001 cool-        Mitochondrial DNA copy number Length Quantification qPCR Assay
ing system and oxygen gas supplied. Data was derived as a single point     Kit (M8938, ScienCell), respectively.
reading (n = 1). The average relative error ranges from 0.07%–0.59%.
                                                                           Histology
Colorimetric and enzyme-linked immunosorbent assays (ELISA)                Investigators performing histology and analysis were blinded to the
The levels of ALT, AST, cholesterol and IL-6 in mouse serum were meas-     genotype and treatment group.
ured using Alanine Transaminase Activity Assay Kit (ab105134, abcam),
Aspartate Aminotransferase Activity Assay Kit (ab105135, abcam), Cho-      Haematoxylin and eosin staining. Mouse vWAT were fixed in 10%
lesterol Assay Kit (ab65390, Abcam), and Mouse IL-6 Quantikine ELISA       neutral-buffered formalin (NBF) for 48 h, embedded in paraffin, cut
Kit (M6000B, R&D Systems), respectively. The levels of triglyceride in     into 4-μm sections followed by haematoxylin and eosin staining
mouse livers and serum were measured using Triglyceride Assay Kit          according to the standard protocol. Lipid droplet areas were quantified
(ab65336, Abcam). Total collagen content in mouse livers, gastroc-         by ImageJ (version 1.53t, NIH) with the adipocytes tools plugin (https://
nemius, and vWAT were measured using Quickzyme Total Collagen              github.com/MontpellierRessourcesImagerie/imagej_macros_and_
assay kit (QZBtotco15, Quickzyme Biosciences). The levels of IL-6, IL-8    scripts/wiki/Adipocytes-Tools) from 5 randomly selected fields at 200×
and IL-11 in equal volumes of cell culture media collected from experi-    magnification in vWAT images per mouse, and 5 mice per group were
ments with primary human cells were quantified using Human IL-8/           assessed. The mean value of lipid droplet areas per field was plotted
CXCL8 Quantikine ELISA Kit (D8000C, R&D Systems), Human IL-6               for the final data presentation.
Quantikine ELISA Kit (D6050, R&D Systems), Human IL-11 Quantikine
ELISA kit (D1100, R&D Systems). All ELISA and colorimetric assays were     Immunohistochemistry. Four-micrometre mouse vWAT sections
performed according to the manufacturer’s protocol. Triglyceride           were dewaxed with histoclear and a gradient ethanol wash, followed
Assay Kit (ab65336, Abcam),                                                by permeabilization using 1% Triton X-100 for 10 min and antigen
                                                                           retrieval process with Reveal Decloaker (RV1000M, Biocare Medi-
Immunoblotting                                                             cal) using a double boiler method at 110 °C for 20 min. Slides were
Western blots were carried out on total protein extracts from liver,       allowed to cool in the container together with the Reveal Decloaker
gastrocnemius, and vWAT tissues, which were homogenized in RIPA            solution for 10 min under running water. Double blocking was
Lysis and Extraction Buffer (89901, Thermo Fisher Scientific) contain-     achieved with (1) H2O2 for 10 min and (2) 2.5% normal horse serum
ing protease and phosphatase inhibitors (A32965 and A32957, Thermo         for 1 h (S-2012, Vector Labs). vWAT sections were incubated overnight
Fisher Scientific). Protein lysates were separated by SDS–PAGE, trans-     at 4 °C with primary antibody (CD68, 1:100 in PBST) and visualized
ferred to PVDF membranes, blocked for 1 h with 3% BSA, and incubated       by probing with Horse Anti-Rabbit IgG Polymer Kit (MP-7401, Vec-
overnight with primary antibodies (1:1,000 in TBST). This study was        tor Labs) for 1 h at 37 °C and ImmPACT DAB Peroxidase Substrate
conducted over six years, and western blots were performed on many         Kit (SK-4105, Vector Labs). Haematoxylin (H-3401, Vector Labs) was
tissues, the smallest of which provided limited protein for blotting. To   used to counterstain the nuclei prior to imaging by light microscopy
conserve antibody usage and maximize data output, membranes were           (Olympus IX73).
often cut at the appropriate molecular weight markers and probed
with different antibodies. In all instances, equal loading of protein      Immunofluorescence. Young (10-week) and aged (100-week) Il11EGFP/+
lysates per membrane was ensured. Protein bands were visualized            and aged wild-type Il11+/+ mice underwent perfusion-fixation with
using SuperSignal West Femto Maximum Sensitivity Substrate detec-          PBS and 4% paraformaldehyde for multi-organ collection at terminal
tion system (34096, Thermo Fisher Scientific) with the appropriate         euthanasia. Mouse liver, vWAT and gastrocnemius were further fixed
HRP secondary antibodies (1:1,000 in TBST). Raw uncropped blots are        in 4% paraformaldehyde at 4 °C and serial 15–30% sucrose dehydration
provided in Supplementary Fig. 1 and semi-quantitative densitometry        over 48 h before they were cryo-embedded in OCT medium. 5 µm sec-
analyses are provided in Supplementary Fig. 2.                             tions were heat antigen retrieved using Reveal Decloaker (RV1000M,
                                                                           Biocare), permeabilized with 0.5% Triton X-100, and blocked with 5%
Quantitative PCR with reverse transcription                                normal horse serum before probing with primary antibodies diluted
Total RNA was extracted from cells or snap-frozen tissues using TRIzol     in 2.5% normal horse serum at 4 °C overnight. The antibody dilutions
Reagent (15596026, Thermo Fisher Scientific) and RNeasy Mini Kit           used for immunofluorescence studies are as follows: adiponectin, GFP,
(74104, Qiagen). PCR amplifications were performed using iScript           PDGFRα and SLC10A1 (1:100); CD31, FHL1 and SM22α (1:200). Alexa
cDNA Synthesis Kit (1708891, Bio-Rad). Gene expression analysis was        Fluor-conjugated secondary antibodies (1:300 in 2.5% normal horse
performed with QuantiNova SYBR Green PCR Kit (208056, Qiagen)              serum) were incubated for 2 h at room temperature for visualization.
technology using StepOnePlus (Applied Biosystem). Expression data          Autofluorescence was quenched with 0.1% Sudan Black B for 20 min.
were normalized to GAPDH mRNA expression and fold change was               DAPI was included for nuclear staining before mounting and sealed.
calculated using 2−∆∆Ct method. The primer sequences are provided          Photomicrographs were randomly captured by researchers blinded
in the Supplementary Table 8.                                              to the strain and age groups.
                                                                            groups were performed by two-way ANOVA and corrected with Sidak’s
RNA-seq libraries                                                           multiple comparisons. Two-way repeated measures ANOVA (Geisser–
Total RNA was isolated from liver, fat and skeletal muscle of mice          Greenhouse correction) with Sidak’s multiple comparisons was applied
receiving either IgG or X203 using RNeasy Mini Kit (74104, Qiagen) and      to temporal sampling in paired subjects for GTT, ITT and body weight.
quantified using Qubit RNA Broad Range Assay Kit (Q10210, Thermo            Individual endpoint frailty indices were ranked and compared using
Fisher Scientific). RNA quality scores (RQS) were assessed using the        two-tailed Mann–Whitney test to compare (1) old Il11−/− versus wild-type
RNA Assay (CLS960010, PerkinElmer) and DNA 5 K/RNA/CZE HT Chip              females; (2) old Il11−/− versus wild-type males; or (3) IgG versus X203
(760435, PerkinElmer) on a LabChip GX Touch HT Nucleic Acid Analyzer        groups in females, and the Kruskal–Wallis test with Dunn’s multiple
(CLS137031, PerkinElmer). TruSeq Stranded mRNA Library Prep kit             comparisons of untreated, IgG and X203 treatment groups in males.
(20020594, Illumina) was used to assess transcript abundance fol-           The two-population proportions analysis (two-tailed) was used for
lowing the manufacturer’s instructions. In brief, poly(A) + RNA was         comparing the difference in the proportion of cancer occurrence and
purified from 1 µg of total RNA with RQS > 6, fragmented, and used          seminal vesicle dilatation between two groups. The criterion for statisti-
for cDNA conversion, followed by 3′ adenylation, adapter ligation, and      cal significance was set at P < 0.05. For the lifespan studies, differences
PCR amplification. The final libraries were quantified using Qubit DNA      in survival between the experimental groups (Il11−/− versus wild-type
Broad Range Assay Kit (Q32853, Thermo Fisher Scientific) according          or X203 versus IgG) were compared using the Kaplan–Meier method
to the manufacturer’s guide. The average fragment size of the final         implemented in IBM SPSS (release 29.0.1.0), and statistical significance
libraries was determined using DNA 1 K/12 K/Hi Sensitivity Assay            (P value) was assessed by means of the log-rank (Mantel–Cox) test. In
LabChip (760517, PerkinElmer) and DNA High Sensitivity Reagent Kit          addition to the log-rank test (that gives equal weight to all time points),
(CLS760672, PerkinElmer). Libraries with unique dual indexes were           we used the Wilcoxon test (that gives more weight to deaths at early
pooled and sequenced on partial lanes targeting ~50 M reads per sam-        time points), which provided significant results in all comparisons,
ple on a HiSeq or a NovaSeq 6000 sequencer (Illumina) using 150-bp          therefore yielding a similar conclusion to reject the null hypothesis.
paired-end sequencing chemistry.                                            Both survival comparison methods are non-parametric tests based on
                                                                            the chi-square statistic and provide two-tailed P values. The complete
Data processing and analysis for RNA-seq                                    list of exact p-values and terms for supporting statistical information
Fastq files were generated by demultiplexing raw sequencing files           is provided in Supplementary Table 9.
(.bcl) with Illumina’s bcl2fastq v2.20.0.422 with the --no-lane-splitting
option. Low quality read removal and adapter trimming was car-              Reporting summary
ried out using Trimmomatic V0.36 with the options ILLUMINACLIP:             Further information on research design is available in the Nature Port-
<keepBothReads > =TRUE MAXINFO:35:0.5 MINLEN:35. Reads                      folio Reporting Summary linked to this article.
were mapped to the Mus musculus GRCm39 using STAR v.2.7.9a
with the options --outFilterType BySJout --outFilterMultimap­
Nmax 20 --alignSJoverhangMin 8 --alignSJDBoverhangMin 1                     Data availability
--outFilterMismatchNmax 999 --alignIntronMin 20 --alignIntronMax            All data are available within the Article or Supplementary Information.
1000000 --alignMatesGapMax 1000000 in paired-end, single pass               The RNA-seq data reported in this paper are available on the Short Read
mode. Read counting at the gene-level was carried out using subread         Archive with Bioproject ID: PRJNA939262. Datasets used for analysis
v.2.0.3: -t exon -g gene_id -O -s 2 -J -p -R -G. The Ensembl release 104    in this study are as follows: Ensembl release 104 M. musculus GRCm39
M. musculus GRCm39 GTF was used as annotation to prepare STAR               gene annotations (GRCm39, https://asia.ensembl.org/info/data/ftp/
indexes and for FeatureCounts. Principal component analysis clus-           index.html), MSigDB Hallmark (v.7.5.1, https://www.gsea-msigdb.org/
tered samples into tissue-types and conditions. Outlier samples that        gsea/msigdb/human/collections.jsp) and MitoCarta (v3.0, https://
did not cluster with the expected group were removed. Differentially        www.broadinstitute.org/mitocarta/mitocarta30-inventory-mammal
expressed genes were identified using R v4.2.0 using the Bioconduc-         ian-mitochondrial-proteins-and-pathways). Source data are provided
tor package DESeq2 v1.36.0 using the Wald test for comparisons. IgG         with this paper.
samples were used as the reference level for comparison with anti-IL-11
(X203) samples for vWAT, liver, and gastrocnemius. Mitocarta v3.0 gene      50. Widjaja, A. A. et al. Targeting endogenous kidney regeneration using anti-IL11 therapy in
                                                                                acute and chronic models of kidney disease. Nat. Commun. 13, 7497 (2022).
list was downloaded and TPM values in Fat IgG and anti-IL-11 samples        51. Dong, J. et al. Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the
were plotted using pheatmap R package for genes which had TPM ≥ 5               transition from NAFLD to NASH. Nat. Commun. 12, 66 (2021).
in at least one condition. Gene set enrichment analysis was carried         52. Ackert-Bicknell, C. L. et al. Aging research using mouse models. Curr. Protoc. Mouse Biol.
                                                                                5, 95–133 (2015).
out using the fgsea v.1.22.0 R package for MSigDB Hallmark (msigdbr
v.7.5.1) and MitoCarta v3.0 gene sets with 100,000 iterations. The ‘stat’
value quantified by DESeq2 was used to rank the genes, as an input for      Acknowledgements The authors thank M. M. Dy Varela, C. H. Lee and all other members of the
                                                                            Duke–NUS vivarium team for their invaluable assistance in monitoring and overseeing the care
the enrichment analysis.
                                                                            for our mice used in this study; and Enleofen and Boehringer Ingelheim for the permission to
                                                                            use X203 in this study. This research is supported by the National Medical Research Council
Statistical analysis                                                        (NMRC) MOH-STaR21nov-0003 (S.A.C.), NMRC Centre Grant to the NHCS (S.A.C.), MOH‐
                                                                            CIRG18nov‐0002 (S.A.C.), Tanoto Foundation (S.A.C.), Leducq Foundation (S.A.C.), NMRC/
Statistical analyses were performed using GraphPad Prism software           OFYIRG/0053/2017 (A.A.W.), NMRC MOH-OFIRG21nov-0006 (A.A.W.), NMRC MOHOFLCG22may-
(version 10). Datasets were tested for normality with Shapiro–Wilk tests.   0003 (A.A.W.), Khoo Foundation (A.A.W. and E.A.), and Goh Foundation (S.A.C. and A.A.W.).
For normally distributed data, two-tailed Student’s t-tests or one-way      N.H. is supported by Leducq Foundation 16CVD03, ERC advanced grant under the European
                                                                            Union Horizon 2020 Research and Innovation Program (AdG788970), and Deutsche
ANOVA were used for analysing experimental setups requiring testing         Forschungsgemeinschaft (DFG-German Research Foundation) SFB 1470 HFpEF. W.-W.L. is
of two conditions or more than two conditions, respectively. P values       supported by A*STAR AME YIRG (A2084c0157). B.K.S. is supported by MOH-OFIRG19may-0002.
were corrected for multiple testing according to Dunnett (when several      The D.J.W. lab is supported by the Wellcome Trust Grant 098565/Z/12/Z and the MRC grant
                                                                            MC-A654-5QB40. The J.G. lab is supported by MRC (MC-U120085810) and CRUK (C15075/
experimental groups were compared to a single control group) or Tukey       A28647) grants. The D.C. lab is supported by the MRC grant MC-A654-5QB10. The S.A.C.
(when several conditions were compared to each other within one             laboratory receives core grant support from the MRC LMS and is also supported by the British
experiment) tests. Non-parametric tests (Kruskal–Wallis with Dunn’s         Heart Foundation’s Big Beat Challenge award to CureHeart (BBC/F/21/220106).

correction in place of ANOVA and Mann–Whitney U test in place of
                                                                            Author contributions A.A.W. and S.A.C. conceived, designed, funded and provided supervision
two-tailed Student’s t-tests) were conducted for non-normally distrib-      for the study. A.A.W., W.-W.L., S.V., B.C., D.M.C., J.W.T.G, B.K.S., J.T., S.S., E.A., B.L.G., M.S. and
uted data. Comparison analysis for two parameters from two different        M.T. performed in vitro and in vivo studies, biochemistry and molecular biology experiments.
Article
W.-W.L., S.Y.L. and C.X. performed histology analysis. C.J.P. performed RNA-seq. R.L. and L.H          named inventor in MRC and Imperial College patents related to senolytic therapies
performed the phenomaster study. A.A.W., W.-W.L., S.C., R.L., B.K.S., N.A.S., N.H., E.P., L.H. and     (the patents are not related to the work presented here). The other authors declare no
S.A.C. analysed and interpreted the data. D.J.W., J.G. and D.C. provided intellectual input. A.A.W.,   competing interests.
W.-W.L. and S.A.C. prepared the manuscript with input from co-authors.
                                                                                                       Additional information
Competing interests A.A.W., B.C., B.K.S., S.S. and S.A.C. are co-inventors of a patent family that     Supplementary information The online version contains supplementary material available at
includes: WO2022090509A (methods to extend healthspan and treat age-related diseases)                  https://doi.org/10.1038/s41586-024-07701-9.
and WO2018109174 (IL-11 antibodies). S.S. and S.A.C. are co-founders and shareholders of               Correspondence and requests for materials should be addressed to Anissa A. Widjaja or
Enleofen Bio Pte Ltd and VVB Bio Pte Ltd. A.A.W. had consulted for VVB Bio on work unrelated           Stuart A. Cook.
to the study presented here. J.G. has acted as a consultant for Unity Biotechnology, Geras Bio,        Peer review information Nature thanks Stephan Herzig and the other, anonymous, reviewer(s)
Myricx Pharma and Merck KGaA. Pfizer and Unity Biotechnology have funded research in the               for their contribution to the peer review of this work. Peer review reports are available.
J.G. laboratory unrelated to the work presented here. J.G. owns equity in Geras Bio. J.G. is a         Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | Age-dependent expression of IL11 in varied cell types       (n = 5/group). d WB of IL11 and GAPDH in the liver, vWAT and gastrocnemius
across tissues. a Western blots (WB) of total ERK1/2, p90RSK, LKB1, AMPK,          from 12-week-old and 110-week-old male and female mice (n = 3/group).
mTOR, p70S6K, and S6RP in livers from 12, 25, 50, 75, and 110-week-old male        e-g Representative immunofluorescence images (scale bars, 100 µm) of EGFP
mice for the respective phosphoproteins shown in Fig. 1b. b WB of IL11 and         expression in the livers, vWAT, and gastrocnemius, colocalized with parenchymal
GAPDH in visceral gonadal white adipose tissue (vWAT) and gastrocnemius            cell markers Adiponectin (AdipoQ) in vWAT and Four and a half LIM domains
from 12, 25, 50, 75, and 110-week-old male mice (n = 5/group). c WB of p-ERK1/2,   (FHL1) in gastrocnemius, endothelial cells (CD31), smooth muscle transgelin
p-p90RSK, p-LKB1, p-AMPK, p-mTOR, p-p70S6K, p-S6RP, and their respective           (SM22α), and pan-fibroblast marker (PDGFRα) of 10 and 110-week old Il11-EGFP
total proteins in gastrocnemius from 12, 25, 50, 75, and 110-week-old male mice    mice (representative dataset from n = 3/group).
Article




Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Beneficial signalling, metabolic, inflammation and                   n mitochondria DNA (mtDNA) copy number from young and old male and
ageing biomarker effects associated with Il11ra1 deletion. a WB of total                    female WT and Il11ra1−/− mice. d-l Data are shown as mean ± SD. d-n young male
proteins in livers for Fig. 1e. WB showing the activation status of ERK1/2, p90RSK,         WT, n = 8 (i-n, except for i (Acc and Fasn), n = 7); young male Il11ra1−/−, n = 7
LKB1, AMPK, mTOR, p70S6K, S6RP, and protein expression levels of p16, p21                   (i-n, except for i (Acc and Fasn), n = 8); old male WT, n = 11 (e (liver), f-n), n = 12
and GAPDH in b vWAT and c gastrocnemius from 10 and 110-week-old male WT                    (d, e (vWAT and gastrocnemius); old male Il11ra1−/−, n = 15 (e (liver)), n = 16 (d, f-l),
and Il11ra1−/− mice (n = 5/group). d body temperatures, e indexed weights of liver,         n = 17 (e (vWAT and gastrocnemius), i (Ccl5), m-n); young female WT, n = 7; young
vWAT and gastrocnemius, and f the levels of liver triglycerides (TG), g serum               female Il11ra1−/−, n = 8; old female WT, n = 14 (e (liver and vWAT)), n = 15
cholesterol, and h serum triglycerides of 110-week-old male and female WT and               (d, e (gastrocnemius), f-n); old female Il11ra1−/−, n = 12 (m-n), n = 13 (d-l); two-way
Il11ra1−/− mice. Relative gene expression levels of i Ccl2, Ccl5, Tnfα, Il1β, Il6, j Acc,   ANOVA with Sidak’s correction. For gel source data, see Supplementary Fig. 1.
Fasn and Srebp1c in livers, and serum levels of k ALT and l AST in young and old            BW: body weight; FC: fold change.
male and female WT and Il11ra1−/− mice. Gastrocnemius m telomere length and
Article




Extended Data Fig. 3 | IL11 causes ERK and mTORC1-dependent senescence         the supernatant of IL11-stimulated primary human hepatocytes (6 and 24 h)
and senescence-associated secretory phenotypes. a-d, f,g Data for IL11         as measured by Olink proximity extension assay (n = 4/group). Concentrations
(24 h)-stimulated primary human cells in the presence of either DMSO, U0126,   of f IL6 and g IL8 in the hepatocyte supernatant (as measured by ELISA).
or rapamycin (n = 6/group). a-b WB showing the activation status of ERK1/2,    a-d, f-g IL11 (5 ng/ml for HCF, 10 ng/ml for hepatocytes), U0126 (10 µM),
mTOR, p16, p21, Cyclin D1, and PCNA protein expression by WB from IL11-        rapamycin (10 nM). c-g Data are shown as mean ± SD. c, d, f, g One-way ANOVA
stimulated a primary human cardiac fibroblasts (HCFs) and b hepatocytes.       with Tukey’s correction; e one-way ANOVA with Dunnett’s correction. For gel
Levels of secreted c IL6 and d IL8 by ELISA from HCF supernatant. e Relative   source data, see Supplementary Fig. 1.
levels of IL6, IL8, LIF, VEGFA, HGF, CCL2, CXCL1, CXCL5, CXCL6, and CCL20 in
Extended Data Fig. 4 | See next page for caption.
Article
Extended Data Fig. 4 | Inhibition of IL11 signalling reduces replicative            from HCFs P4 that were stimulated for 8, 24, 48, and 72 h with media collected
senescence, inflammation, ageing biomarkers, and metabolic decline in               from HCFs P14 that had been grown and passaged in the presence of either IgG
human cardiac fibroblasts. a-c Data for HCF at passage 4 (P4), 7, 10, and 14 that   or anti-IL11RA (X209; 2 µg/ml) from P2 (n = 4/group). e Telomere length (n = 6/
had been passaged in the presence of either IgG or anti-IL11RA (X209; 2 µg/ml)      group) and f mtDNA copy number (n = 6/group) and seahorse assay (n = 8/group)
from P2. a WB of total and p-ERK1/2, p-p90RSK, p-LKB1, p-AMPK, p-mTOR,              showing g mitochondrial oxygen consumption rate (OCR), h changes in OCR
p-p70S6K, p-S6RP, p-NFκB, p-STAT3, p16, p21, PCNA, Cyclin D, and GAPDH              during basal respiration and ATP production states, and i oxidative and glycolytic
(n = 6/group). b Immunofluorescence images (scale bars, 100 μm; representative      energy phenotypes at baseline in HCFs P4 and P14 either untreated or in the
datasets from n = 7/group) and quantification of intensity/area (n = 14/group)      presence of either IgG or anti-IL11RA (X209; 2 µg/ml). b, c, e-i Data are shown as
for p16 and p21 staining. c IL11, IL6 and IL8 levels in the supernatant based on    mean ± SD. b, c Two-way ANOVA with Sidak’s correction, e, f, h one-way ANOVA
ELISA (n = 6/group). d WB showing the expression levels of p16, p21, and GAPDH      with Tukey’s correction. For gel source data, see Supplementary Fig. 1.
Extended Data Fig. 5 | Female Il11−/− mice are protected from age-associated        S6RP activation and p16, p21, and GAPDH protein expression levels (n = 6/group)
frailty and inflammation and have advantageous metabolic profiles. a Body           in gastrocnemius, m relative pro-inflammatory gene expression (Ccl2, Ccl5,
temperatures, b front paw grip strength, serum levels of c ALT, d AST, area under   Tnfα, Il1β and Il6) levels in vWAT, and n serum IL6 levels from young (12-week-old)
the curves (AUC) of e glucose tolerance tests (GTT) and f insulin tolerance tests   and old (105-week-old) female WT and Il11−/− mice. a-j, m-n Data are shown as
(ITT), weights of g skeletal muscle (gastrocnemius and soleus) and h liver          mean ± SD, two-way ANOVA with Sidak’s correction (young WT, n = 5 ( j), n = 8
(normalised/indexed to BW), i liver triglyceride (TG) levels, j indexed brown       (a, c-i, m-n), n = 10 (b); young Il11−/−, n = 7 ( j), n = 9 (a-i, m-n); old WT, n = 16; old
adipose tissues (BAT) weight, k WB of total proteins for the respective phospho     Il11−/−, n = 16 ( j), n = 18 (a-i, m-n). For gel source data, see Supplementary Fig. 1.
proteins in vWAT as shown in Fig. 2j,l WB showing ERK1/2, mTOR, p70S6K, and         AU: arbitrary units; BW: body weight; FC: fold change.
Article




Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Old male Il11−/−mice are protected from age-associated   mice (n = 10/group). i Faecal caloric density as measured by bomb calorimetry
metabolic decline. a Representative image of 108-week-old WT and Il11−/− male   in 95–105-week-old male WT and Il11−/− mice (n = 10/group). Indexed weight of
mice. b Body weights, c percentages of fat and lean mass (normalised to BW),    j gastrocnemius k, soleus, l liver, m vWAT, subcutaneous WAT (scWAT), and BAT.
d frailty scores, e body temperatures, f full body and forepaw grip strength    b-g, i-m Data are shown as mean ± SD. b-g, j-m Two-way ANOVA with Sidak’s
measurements, g glucose and insulin tolerance tests (GTT and ITT) from young    correction (young WT and Il11−/−, n = 6 (m (scWAT and BAT)), n = 9 (b-g, j-l,
(12-week-old) and old (105-week-old) male WT and Il11−/− mice. h Respiratory    m (vWAT)); old WT, n = 12 (m (scWAT and BAT)), n = 15 (b-g, j-l, m (vWAT)); old
exchange ratio (RER) measurement at day 2 (top; 24 h) and assessment of RER     Il11−/−, n = 12 (f-g, m (scWAT and BAT)), n = 14 (b-e,j-l, m (vWAT)); i two-tailed
(second panel), cumulative food intake, and locomotive activities using the     Mann Whitney test. AU: arbitrary units; BW: body weight; FC: fold change.
phenomaster system over a 5-day period in 68–70-week-old male WT and Il11−/−
Article




Extended Data Fig. 7 | Anti-IL11 therapy improves muscle strength and                 f AST, indexed weight of g soleus, h scWAT and BAT, and i WB of total proteins
metabolic health in old male mice. a-k Data for anti-IL11 therapeutic dosing          for the respective phospho-proteins in vWAT shown in Fig. 3m (n = 6/group).
experiment as shown in Schematic Fig. 3a in which IgG or X203 were administered       j telomere length and k mtDNA copy number. a, c-h, j-k Data are shown as
to male mice starting from the age of 75 weeks. a Forepaw grip strength, b RER        mean ± SD. a, d-h, j-k One-way ANOVA with Tukey’s correction (75-week-old
measurements, cumulative food intake, and locomotive activities as measured           control, n = 6 (h), n = 10 (a), n = 14 (d-g, j-k); untreated 100-week-old, n = 6; IgG
by phenomaster for 5 days on IgG/X203-treated old (81-week-old) male mice − 6         100-week-old, n = 13; X203 100-week-old, n = 12); c two-tailed Mann Whitney
weeks after IgG/X203 administration was started (n = 10/group). c Faecal caloric      test; j two-tailed Student’s t-test. For gel source data, see Supplementary Fig. 1.
density as measured by bomb calorimetry in IgG and X203-treated 115-week-old          BW: body weight; FC: fold change.
male mice (IgG, n = 8; X203, n = 10). Serum levels of d cholesterol, TG, e IL6, and
Extended Data Fig. 8 | Therapeutic inhibition of IL11 reduces age-associated       lean mass percentage, and d area under the curve (AUC) of GTT and ITT.
metabolic dysfunction, frailty and sarcopenia in female mice. a Schematic          e Frailty scores at starting (75-week-old) and end-point (100-week-old). f-g Full
of anti-IL11 (X203) therapeutic dosing experiment in old female mice for           body and front paw grip strength at end-point (100-week-old) and changes in
experiments shown in (b-h; IgG, n = 10 (g), n = 11 (b-f, h); X203, n = 13). Mice   full body and front paw grip strength over 25 weeks of treatment (values at
were given either X203 or an IgG control antibody (40 mg/kg, every 3 weeks)        end-point (100-week-old) - values at starting point (75-week-old)). h Body
starting from 75 weeks of age for a duration of 25 weeks. Created with             temperatures. b-d, f-h Data are shown as mean ± SD. b Two-way ANOVA,
BioRender.com. b Body weights across time. c-d Changes (Δ; values at               c-h two-tailed Student’s t-test except for d Δ AUC GTT, which was analysed by
end-point (100-week-old) - values at starting point (75-week-old)) in c fat and    two-tailed Mann Whitney test. AU: arbitrary units; BW: body weight.
Article




Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | Beneficial effects of anti-IL11 in aged white adipose            untreated 100-week-old, n = 6; IgG-treated 100-week-old n = 13; X203-treated
tissue. a. Violin plot of Transcripts per million (TPM) values of senescence            100-week-old, n = 12) and g female WT and Il11−/− mice (young WT, n = 5; young
genes (based on Tabula Muris Senis consortium) in vWAT, liver, gastrocnemius            Il11−/−, n = 7; old WT and Il11−/−, n = 16/group). h Relative vWAT mRNA expression
samples from mice receiving either IgG or anti-IL11 as shown in schematic               of pro-inflammatory markers (Ccl2, Ccl5, Tnfα, Il1β, Il6) in young (10-week-old)
Fig. 3a. b. Relative Ucp1 mRNA from 10-week-old and 110-week-old male and               and old (110-week-old) male and female WT and Il11ra1−/− mice. a, c, d, e Liver
female WT and Il11ra1−/− mice (vWAT). c. Heatmap showing row-wise scaled TPM            and gastrocnemius (n = 8/group), vWAT IgG, n = 7; vWAT anti-IL11, n = 6;
values for the gene-list in Mitocarta 3.0. (no. of genes = 1,019 with TPM > = 5 in at   b, h young male WT, n = 8; young male Il11ra1−/−, n = 7; old male WT, n = 11; old
least one condition). d. A lollipop plot for top 50 significant Mitocarta 3.0           male Il11ra1−/−, n = 14; young female WT, n = 7; young female Il11ra1−/−, n = 8; old
pathways (p-adj<0.05) in enrichment analysis using fgsea R package. No                  female WT, n = 15; old female Il11ra1−/−, n = 12. a Data are shown as violin plots
negative NES was found to be significant. e. Distribution of RNA-seq reads at           with median ± min-max; b, f-h data are shown as mean ± SD. b, g, h Two-way
the Clstn3 locus from IgG or anti-IL11-treated vWAT. Relative Ucp1 mRNA                 ANOVA with Sidak’s correction; e one-way ANOVA with Tukey’s correction.
expression levels in BAT from f therapeutic dosing group (75-week-old, n = 6;
Article




Extended Data Fig. 10 | Gross appearance of mice receiving anti-IL11 versus
IgG in lifespan studies. Representative images of 130-week-old male (top) and
female (bottom) mice from the lifespan therapeutic dosing study where mice
received either IgG (mice on the left) or anti-IL11 (X203; mice on the right) from
75 weeks of age until death.
α
    κ
κ
    κ

κ
     −−



−−
          −−

```
